WO2015148379A1 - Monobactam organic compounds for the treatment of bacterial infections - Google Patents
Monobactam organic compounds for the treatment of bacterial infections Download PDFInfo
- Publication number
- WO2015148379A1 WO2015148379A1 PCT/US2015/022011 US2015022011W WO2015148379A1 WO 2015148379 A1 WO2015148379 A1 WO 2015148379A1 US 2015022011 W US2015022011 W US 2015022011W WO 2015148379 A1 WO2015148379 A1 WO 2015148379A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- mmol
- compound
- methyl
- Prior art date
Links
- -1 Monobactam organic compounds Chemical class 0.000 title claims description 76
- 238000011282 treatment Methods 0.000 title claims description 28
- 208000035143 Bacterial infection Diseases 0.000 title claims description 23
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 23
- 229960003644 aztreonam Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 410
- 238000000034 method Methods 0.000 claims abstract description 242
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 125
- 125000000623 heterocyclic group Chemical group 0.000 claims description 57
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 229910052717 sulfur Inorganic materials 0.000 claims description 49
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 125000005842 heteroatom Chemical group 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 21
- 241000588914 Enterobacter Species 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 241000894007 species Species 0.000 claims description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 241000607142 Salmonella Species 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 241000589291 Acinetobacter Species 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
- 241000588923 Citrobacter Species 0.000 claims description 12
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 12
- 241000589516 Pseudomonas Species 0.000 claims description 12
- 241000607720 Serratia Species 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 241000588748 Klebsiella Species 0.000 claims description 11
- 241000588771 Morganella <proteobacterium> Species 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 9
- 241000588653 Neisseria Species 0.000 claims description 9
- 241000122971 Stenotrophomonas Species 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 241001453380 Burkholderia Species 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 241000606125 Bacteroides Species 0.000 claims description 7
- 241000589876 Campylobacter Species 0.000 claims description 7
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 4
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims description 2
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 2
- ZROILLPDIUNLSE-UHFFFAOYSA-N 1-phenyl-1h-pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=CC=CC=C1 ZROILLPDIUNLSE-UHFFFAOYSA-N 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 2
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 2
- 208000036209 Intraabdominal Infections Diseases 0.000 claims description 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 244000292604 Salvia columbariae Species 0.000 claims 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 claims 1
- 235000001498 Salvia hispanica Nutrition 0.000 claims 1
- 235000014167 chia Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 103
- 241000894006 Bacteria Species 0.000 abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 16
- 238000009472 formulation Methods 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 229910052740 iodine Inorganic materials 0.000 abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 327
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 251
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 228
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 196
- 239000000243 solution Substances 0.000 description 170
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 167
- 235000019439 ethyl acetate Nutrition 0.000 description 124
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 110
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 238000003756 stirring Methods 0.000 description 103
- 239000011734 sodium Substances 0.000 description 89
- 239000007787 solid Substances 0.000 description 88
- 239000010410 layer Substances 0.000 description 87
- 239000012267 brine Substances 0.000 description 79
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 79
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 78
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 77
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 71
- 238000005160 1H NMR spectroscopy Methods 0.000 description 68
- 239000000543 intermediate Substances 0.000 description 61
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 56
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 51
- 238000010898 silica gel chromatography Methods 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 46
- 239000002253 acid Substances 0.000 description 41
- 239000000843 powder Substances 0.000 description 40
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 235000019253 formic acid Nutrition 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000012071 phase Substances 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- 239000003607 modifier Substances 0.000 description 37
- 230000002441 reversible effect Effects 0.000 description 37
- 238000002953 preparative HPLC Methods 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 35
- 239000002955 immunomodulating agent Substances 0.000 description 32
- 229940121354 immunomodulator Drugs 0.000 description 31
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 30
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 30
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000010511 deprotection reaction Methods 0.000 description 25
- 230000001404 mediated effect Effects 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 24
- 230000002584 immunomodulator Effects 0.000 description 23
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 21
- XMBSMMCPKFDGEO-ZETCQYMHSA-N (2s)-2-amino-5-[[amino-(2-methoxyethylamino)methylidene]amino]pentanoic acid Chemical compound COCCNC(=N)NCCC[C@H](N)C(O)=O XMBSMMCPKFDGEO-ZETCQYMHSA-N 0.000 description 20
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 239000007821 HATU Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 18
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229910052805 deuterium Inorganic materials 0.000 description 18
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 108010074708 B7-H1 Antigen Proteins 0.000 description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- KHUNFTAJVUPPCY-UHFFFAOYSA-N azetidine-1-sulfonic acid Chemical compound OS(=O)(=O)N1CCC1 KHUNFTAJVUPPCY-UHFFFAOYSA-N 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000002002 slurry Substances 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 10
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 9
- 241000588722 Escherichia Species 0.000 description 9
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 229960003301 nivolumab Drugs 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 8
- 239000003781 beta lactamase inhibitor Substances 0.000 description 8
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 8
- 230000000139 costimulatory effect Effects 0.000 description 8
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229940126546 immune checkpoint molecule Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
- RBZRMBCLZMEYEH-UHFFFAOYSA-N 1h-pyrazol-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1C=CC=N1 RBZRMBCLZMEYEH-UHFFFAOYSA-N 0.000 description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 229960002621 pembrolizumab Drugs 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000019260 propionic acid Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 229940125565 BMS-986016 Drugs 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 101150030213 Lag3 gene Proteins 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 5
- 239000011755 sodium-L-ascorbate Substances 0.000 description 5
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 241000589513 Burkholderia cepacia Species 0.000 description 4
- 102100024263 CD160 antigen Human genes 0.000 description 4
- DXBDZEMWBVYYRJ-QUCCMNQESA-N COc1ccc(CN2[C@H](COS(C)(=O)=O)[C@H](NC(=O)OCc3ccccc3)C2=O)c(OC)c1 Chemical compound COc1ccc(CN2[C@H](COS(C)(=O)=O)[C@H](NC(=O)OCc3ccccc3)C2=O)c(OC)c1 DXBDZEMWBVYYRJ-QUCCMNQESA-N 0.000 description 4
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 4
- 241000588919 Citrobacter freundii Species 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 241000588770 Proteus mirabilis Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- MRODUQOWGIDAAI-MJGOQNOKSA-N benzyl n-[(2s,3s)-1-[(2,4-dimethoxyphenyl)methyl]-2-(hydroxymethyl)-4-oxoazetidin-3-yl]carbamate Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)[C@@H](NC(=O)OCC=2C=CC=CC=2)[C@H]1CO MRODUQOWGIDAAI-MJGOQNOKSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- UMXBMEVYOBWMBN-UHFFFAOYSA-N 4-ethynyl-3-methylpyridine Chemical compound CC1=CN=CC=C1C#C UMXBMEVYOBWMBN-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000606124 Bacteroides fragilis Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 241000588917 Citrobacter koseri Species 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 241000588749 Klebsiella oxytoca Species 0.000 description 3
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 3
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000588772 Morganella morganii Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241001135215 Prevotella bivia Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 3
- 229960002379 avibactam Drugs 0.000 description 3
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 229940076266 morganella morganii Drugs 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229950010773 pidilizumab Drugs 0.000 description 3
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical class N1N=NC(=C1)* 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 2
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 2
- OADYBXHYXPEGHX-UHFFFAOYSA-N 2h-triazol-4-ylmethanol Chemical compound OCC1=CNN=N1 OADYBXHYXPEGHX-UHFFFAOYSA-N 0.000 description 2
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- MNILDQSRDHCFJG-UHFFFAOYSA-N 3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1OCC2CCC1N2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 2
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- AJJUPMDOLBVEQY-UHFFFAOYSA-M FC(S(=O)(=O)[O-])(F)F.C(#C)C1=C(C=[N+](C=C1)C)C Chemical compound FC(S(=O)(=O)[O-])(F)F.C(#C)C1=C(C=[N+](C=C1)C)C AJJUPMDOLBVEQY-UHFFFAOYSA-M 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- IDGCWCDAEHVKAV-UHFFFAOYSA-M [Cl-].[NH3+]CC=1C=[N+](C=CC1)C.[Cl-] Chemical compound [Cl-].[NH3+]CC=1C=[N+](C=CC1)C.[Cl-] IDGCWCDAEHVKAV-UHFFFAOYSA-M 0.000 description 2
- GHRMWZJGFVZKRV-UHFFFAOYSA-N [I-].C(C)(=O)NCC=1C=[N+](C=CC1)C Chemical compound [I-].C(C)(=O)NCC=1C=[N+](C=CC1)C GHRMWZJGFVZKRV-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001540 azides Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- AYIAXGUYQNLNKV-MJGOQNOKSA-N benzyl n-[(2s,3s)-1-[(2,4-dimethoxyphenyl)methyl]-2-formyl-4-oxoazetidin-3-yl]carbamate Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)[C@@H](NC(=O)OCC=2C=CC=CC=2)[C@H]1C=O AYIAXGUYQNLNKV-MJGOQNOKSA-N 0.000 description 2
- SAKPMXDWJXMKQH-ZJUUUORDSA-N benzyl n-[(2s,3s)-2-(hydroxymethyl)-4-oxoazetidin-3-yl]carbamate Chemical compound OC[C@H]1NC(=O)[C@H]1NC(=O)OCC1=CC=CC=C1 SAKPMXDWJXMKQH-ZJUUUORDSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 101150049515 bla gene Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 229960003324 clavulanic acid Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- JYGYEBCBALMPDC-UHFFFAOYSA-N heptane;propan-2-one Chemical compound CC(C)=O.CCCCCCC JYGYEBCBALMPDC-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940041009 monobactams Drugs 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960005141 piperazine Drugs 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- DSPYCWLYGXGJNJ-UHFFFAOYSA-N tert-butyl n-prop-2-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCC#C DSPYCWLYGXGJNJ-UHFFFAOYSA-N 0.000 description 2
- GMRIOAVKKGNMMV-UHFFFAOYSA-N tetrabutylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[N+](CCCC)(CCCC)CCCC GMRIOAVKKGNMMV-UHFFFAOYSA-N 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- GAWAYYRQGQZKCR-UWTATZPHSA-N (2r)-2-chloropropanoic acid Chemical compound C[C@@H](Cl)C(O)=O GAWAYYRQGQZKCR-UWTATZPHSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- CIDUJQMULVCIBT-MQDUPKMGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N CIDUJQMULVCIBT-MQDUPKMGSA-N 0.000 description 1
- YSGPYVWACGYQDJ-RXMQYKEDSA-N (4s)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde Chemical compound CC1(C)OC[C@@H](C=O)O1 YSGPYVWACGYQDJ-RXMQYKEDSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- FKENQMMABCRJMK-LWOQYNTDSA-N (5r)-3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=S1(=O)C(C)(C)C(C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-LWOQYNTDSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- GAWAYYRQGQZKCR-REOHCLBHSA-N (S)-2-chloropropanoic acid Chemical compound C[C@H](Cl)C(O)=O GAWAYYRQGQZKCR-REOHCLBHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- NFTOEHBFQROATQ-UHFFFAOYSA-N 2,3-dihydrofuran-5-carboxylic acid Chemical compound OC(=O)C1=CCCO1 NFTOEHBFQROATQ-UHFFFAOYSA-N 0.000 description 1
- RHZBRCQIKQUQHQ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetyl chloride Chemical compound C1=CC=C2C(=O)N(CC(=O)Cl)C(=O)C2=C1 RHZBRCQIKQUQHQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- RJRQIGDFUOJBSE-HBMCJLEFSA-N 2-[(2s,3s)-1-[(2,4-dimethoxyphenyl)methyl]-2-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-oxoazetidin-3-yl]isoindole-1,3-dione Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)[C@@H](N2C(C3=CC=CC=C3C2=O)=O)[C@H]1[C@H]1OC(C)(C)OC1 RJRQIGDFUOJBSE-HBMCJLEFSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZHCLIFKUVIFYBY-UHFFFAOYSA-N 2h-tetrazol-5-ylmethanamine Chemical compound NCC1=NN=NN1 ZHCLIFKUVIFYBY-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 1
- KQFBHVJLZVHFFX-UHFFFAOYSA-N 4-bromo-3-methylpyridine;hydrochloride Chemical compound Cl.CC1=CN=CC=C1Br KQFBHVJLZVHFFX-UHFFFAOYSA-N 0.000 description 1
- XLYOGWXIKVUXCL-UHFFFAOYSA-N 4-bromobut-1-yne Chemical compound BrCCC#C XLYOGWXIKVUXCL-UHFFFAOYSA-N 0.000 description 1
- KFBZWZGIZHLUBX-UHFFFAOYSA-N 4-ethynylpyridine;hydrochloride Chemical compound Cl.C#CC1=CC=NC=C1 KFBZWZGIZHLUBX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- DBTMQODRSDEGRZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-oxoethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC=O)C3=CC=CC=C3C2=C1 DBTMQODRSDEGRZ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- CWTZTIQFVQJEEY-CTNGQTDRSA-N C(C1=CC=CC=C1)OC(N[C@@H]1C(N([C@@H]1CN1C(OCC1)=O)CC1=C(C=C(C=C1)OC)OC)=O)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@@H]1C(N([C@@H]1CN1C(OCC1)=O)CC1=C(C=C(C=C1)OC)OC)=O)=O CWTZTIQFVQJEEY-CTNGQTDRSA-N 0.000 description 1
- JOHZSHQWDZJBQV-NEPJUHHUSA-N C(C1=CC=CC=C1)OC(N[C@@H]1C(N[C@@H]1CN1C(OCC1)=O)=O)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@@H]1C(N[C@@H]1CN1C(OCC1)=O)=O)=O JOHZSHQWDZJBQV-NEPJUHHUSA-N 0.000 description 1
- XWZNADAQRJHECS-MJGOQNOKSA-N C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CI)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CI)=O XWZNADAQRJHECS-MJGOQNOKSA-N 0.000 description 1
- PZBDRZXAXLWOHM-NOZRDPDXSA-N C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CN1C(C2=CC=CC=C2C1=O)=O)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CN1C(C2=CC=CC=C2C1=O)=O)=O PZBDRZXAXLWOHM-NOZRDPDXSA-N 0.000 description 1
- GCKCRHLJYRZSKB-MJGOQNOKSA-N C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CN=[N+]=[N-])=O Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CN=[N+]=[N-])=O GCKCRHLJYRZSKB-MJGOQNOKSA-N 0.000 description 1
- YTNBNZXICXLCTP-CTNGQTDRSA-N C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CNCCO)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CNCCO)=O YTNBNZXICXLCTP-CTNGQTDRSA-N 0.000 description 1
- NOZYZIGKLZNFLU-OLZOCXBDSA-N C(C1=CC=CC=C1)OC(N[C@H]1[C@H](NC1=O)CN1N=CC(=N1)CO)=O Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](NC1=O)CN1N=CC(=N1)CO)=O NOZYZIGKLZNFLU-OLZOCXBDSA-N 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- XOZYEUCIUWILGZ-UHFFFAOYSA-M FC(S(=O)(=O)[O-])(F)F.C(#C)C1=CC=[N+](C=C1)C Chemical compound FC(S(=O)(=O)[O-])(F)F.C(#C)C1=CC=[N+](C=C1)C XOZYEUCIUWILGZ-UHFFFAOYSA-M 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010043766 IRX 2 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- LIZDAKJMANCGGC-UHNVWZDZSA-N N1(N=CN=C1)C[C@@H]1[C@@H](C(N1)=O)N Chemical compound N1(N=CN=C1)C[C@@H]1[C@@H](C(N1)=O)N LIZDAKJMANCGGC-UHNVWZDZSA-N 0.000 description 1
- RCLUSOVHCFGOBM-KOLCDFICSA-N NC=1C=NN(C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NC=1C=NN(C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O RCLUSOVHCFGOBM-KOLCDFICSA-N 0.000 description 1
- RZTIJKSGGLAANO-KCJUWKMLSA-N NCC1=NC=NN1C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NCC1=NC=NN1C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O RZTIJKSGGLAANO-KCJUWKMLSA-N 0.000 description 1
- CEOBFFLDGGDYRK-KCJUWKMLSA-N NCC1=NN(C=N1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NCC1=NN(C=N1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O CEOBFFLDGGDYRK-KCJUWKMLSA-N 0.000 description 1
- CSXCIRUQGUJIHI-KOLCDFICSA-N NCC1=NN(N=C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC1(CC1)C(=O)O)=O)=O)S(=O)(=O)O Chemical compound NCC1=NN(N=C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC1(CC1)C(=O)O)=O)=O)S(=O)(=O)O CSXCIRUQGUJIHI-KOLCDFICSA-N 0.000 description 1
- LPHXMDFSHMOABK-XCBNKYQSSA-N NCC1=NN=NN1C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NCC1=NN=NN1C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O LPHXMDFSHMOABK-XCBNKYQSSA-N 0.000 description 1
- TUGHJDZQEWSJLG-KOLCDFICSA-N NCC=1N=NN(C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NCC=1N=NN(C1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O TUGHJDZQEWSJLG-KOLCDFICSA-N 0.000 description 1
- PDZPPRUVRRTUTB-XCBNKYQSSA-N NCC=1N=NN(N1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NCC=1N=NN(N1)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O PDZPPRUVRRTUTB-XCBNKYQSSA-N 0.000 description 1
- WMAPPUYEBLTVAC-ZOFUNIGCSA-N NC[C@@H]1CN(C(O1)=O)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O Chemical compound NC[C@@H]1CN(C(O1)=O)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC(C(=O)O)(C)C)=O)=O)S(=O)(=O)O WMAPPUYEBLTVAC-ZOFUNIGCSA-N 0.000 description 1
- USNQSQVXOXARQK-ZOFUNIGCSA-N NC[C@@H]1CN(C(O1)=O)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC1(CC1)C(=O)O)=O)=O)S(=O)(=O)O Chemical compound NC[C@@H]1CN(C(O1)=O)C[C@H]1N(C([C@H]1NC(C(C=1N=C(SC1)N)=N/OC1(CC1)C(=O)O)=O)=O)S(=O)(=O)O USNQSQVXOXARQK-ZOFUNIGCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CZJIOLXNSPBYNA-RXMQYKEDSA-N NO[C@@H](C(=O)OC(C)(C)C)C Chemical compound NO[C@@H](C(=O)OC(C)(C)C)C CZJIOLXNSPBYNA-RXMQYKEDSA-N 0.000 description 1
- GBYLWGRZVZHUKP-SVRRBLITSA-N N[C@H]1[C@H](NC1=O)CN1C(CCCC1)=O Chemical compound N[C@H]1[C@H](NC1=O)CN1C(CCCC1)=O GBYLWGRZVZHUKP-SVRRBLITSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001341 alkaline earth metal compounds Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- KVBCYCWRDBDGBG-UHFFFAOYSA-N azane;dihydrofluoride Chemical compound [NH4+].F.[F-] KVBCYCWRDBDGBG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- APUSILOSKYNTCM-CTNGQTDRSA-N benzyl N-[(2R,3S)-1-[(2,4-dimethoxyphenyl)methyl]-2-[(5-methyltetrazol-1-yl)methyl]-4-oxoazetidin-3-yl]carbamate Chemical compound C(C1=CC=CC=C1)OC(N[C@H]1[C@H](N(C1=O)CC1=C(C=C(C=C1)OC)OC)CN1N=NN=C1C)=O APUSILOSKYNTCM-CTNGQTDRSA-N 0.000 description 1
- NTPSJXJOYKPRFW-NEPJUHHUSA-N benzyl N-[(3S,4R)-2-oxo-4-(1,2,4-triazol-1-ylmethyl)azetidin-3-yl]carbamate Chemical compound N1(N=CN=C1)C[C@H]1NC([C@H]1NC(OCC1=CC=CC=C1)=O)=O NTPSJXJOYKPRFW-NEPJUHHUSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WTWHRGABQREDOP-FDFHNCONSA-N benzyl n-[(2s,3s)-1-[(2,4-dimethoxyphenyl)methyl]-2-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-oxoazetidin-3-yl]carbamate Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)[C@@H](NC(=O)OCC=2C=CC=CC=2)[C@H]1[C@H]1OC(C)(C)OC1 WTWHRGABQREDOP-FDFHNCONSA-N 0.000 description 1
- CRNGXCUTFVJFOT-YSIASYRMSA-N benzyl n-[(2s,3s)-2-[(1r)-1,2-dihydroxyethyl]-1-[(2,4-dimethoxyphenyl)methyl]-4-oxoazetidin-3-yl]carbamate Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)[C@@H](NC(=O)OCC=2C=CC=CC=2)[C@H]1[C@@H](O)CO CRNGXCUTFVJFOT-YSIASYRMSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
- 229960000662 carumonam Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-O cefepime(1+) Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-O 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 238000003181 co-melting Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AFZSMODLJJCVPP-UHFFFAOYSA-N dibenzothiazol-2-yl disulfide Chemical compound C1=CC=C2SC(SSC=3SC4=CC=CC=C4N=3)=NC2=C1 AFZSMODLJJCVPP-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical group C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960001430 garenoxacin Drugs 0.000 description 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- KQZCRXVJXGYIFM-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CN=C1 KQZCRXVJXGYIFM-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- XJWDCMFCURPARS-UHFFFAOYSA-N n-methyl-1h-1,2,4-triazol-5-amine;hydrochloride Chemical compound Cl.CNC1=NC=NN1 XJWDCMFCURPARS-UHFFFAOYSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- PBMSWVPMRUJMPE-UHFFFAOYSA-N phthalylsulfathiazole Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(S(=O)(=O)\N=C\2SC=CN/2)C=C1 PBMSWVPMRUJMPE-UHFFFAOYSA-N 0.000 description 1
- 229960001106 phthalylsulfathiazole Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- XFGOMLIRJYURLQ-GOKYHWASSA-N razupenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(SC=1)=NC=1C1=C[C@H](C)NC1 XFGOMLIRJYURLQ-GOKYHWASSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229940041030 streptogramins Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960003879 tedizolid Drugs 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GYALMLCJYDIGKG-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-(pyrazole-1-carboximidoyl)carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C(=N)N1C=CC=N1 GYALMLCJYDIGKG-UHFFFAOYSA-N 0.000 description 1
- ZBBGKXNNTNBRBH-ZCFIWIBFSA-N tert-butyl n-[[(2r)-oxiran-2-yl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@@H]1CO1 ZBBGKXNNTNBRBH-ZCFIWIBFSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940034915 thalomid Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- JZEBKFGSLYUDMH-UHFFFAOYSA-N trimethyl-[2-(3-methylpyridin-4-yl)ethynyl]silane Chemical compound CC1=CN=CC=C1C#C[Si](C)(C)C JZEBKFGSLYUDMH-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000010518 undesired secondary reaction Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to novel ⁇ -lactam compounds, and their preparation and use.
- the invention relates to novel ⁇ -lactam compounds where the lactam ring is monocyclic, and their uses to treat bacterial infections, especially those caused by Gram- negative bacteria.
- nosocomial infections are thought to contribute to or cause more than 77,000 deaths per year and cost approximately $5 to $10 billion annually.
- Important causes of Gram-negative resistance include extended-spectrum ⁇ - lactamases (ESBLs), serine carbapenemases (KPCs) and metallo-3-lactamases (for example NDM-1 ) in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis, high- level third-generation cephalosporin (AmpC) ⁇ -lactamase resistance among Enterobacter species and Citrobacter freundii, and multidrug-resistance genes observed in Pseudomonas, Acinetobacter, and Stenotrophomonas.
- the problem of antibacterial resistance is compounded by the existence of bacterial strains resistant to multiple antibacterials. For example, Klebsiella pneumonia harboring NDM-1 metallo ⁇ -lactamase carries frequently additional serines-lactamases on the same plasmid that carries the NDM-1.
- the invention includes novel compounds, pharmaceutical formulations including the compounds, and methods of using such compounds and compositions for treatment of patients with bacterial infections.
- the compounds are monobactams, which comprise a monocyclic beta-lactam ring, and which typically act by inhibition of penicillin-binding proteins (PBPs), which are involved in biosynthesis of peptidoglycans required for normal bacterial cell walls.
- PBPs penicillin-binding proteins
- Some known members of this class include aztreonam and carumonam.
- Other monobactam compounds are disclosed in WO2013/1 10643 and WO2012/073138. The compounds are primarily effective against Gram-negative bacteria.
- the compounds of the invention can be used to treat infection caused by
- Enterobacteriaceae includingSa/mone//a, E. coli, Klebsiella pneumoniae, Proteus,
- Enterobacter, Serratia, and Citrobacter including pathogens such as KPC producing Klebsiella pneumoniae that are less susceptible to previous monobactams like aztreonam, as well as non-fermenting bacteria, including Pseudomonas aeruginosa, Acinetobacter, Burkholderia, Moraxella and Stenotrophomonas.
- pathogens such as KPC producing Klebsiella pneumoniae that are less susceptible to previous monobactams like aztreonam, as well as non-fermenting bacteria, including Pseudomonas aeruginosa, Acinetobacter, Burkholderia, Moraxella and Stenotrophomonas.
- the compounds of the invention can be used alone or in combination with other antibiotics, and can be used in combination with compounds such as beta-lactamase inhibitors that potentiate the activity of the compounds of the invention against certain pathogens or reduce the frequency or extent of bacterial resistance to the compounds of the invention against certain pathogens.
- Suitable beta-lactamase inhibitors for use in combination with the compounds of the invention include avibactam, tazobactam, sulbactam and clavulanic acid.
- the invention provides compounds of Formula (I):
- Z is CR 4 or N
- R 1 is H or C1-C4 alkyl
- R 2 is selected from the group consisting of H, C1-C4 alkyl, and -COOH
- R 1 and R 2 taken together with the carbon to which they are attached form a ring selected from a C3-C6 cycloalkyl ring and a 4-6 membered heterocyclic ring containing up to two heteroatoms selected from N, O and S as ring members;
- R 3 is selected from H, -COOH, and -L 1 -W-(CH 2 ) 0 - 2 -X-R 5 ;
- R 4 is H or halo
- each L 1 is independently a straight chain or branched Ci_ 4 alkylene
- W is a bond, O, NH or S
- X is phenyl, or a 5-6 membered heteroaryl ring containing 1 -3 heteroatoms selected from N, O and S as ring members; where the phenyl and 5-6 membered heteroaryl are optionally substituted with one or two groups selected from Ci_ alkyl, hydroxy, -CN, F, Ci_ alkoxy, -NH 2 , -NH(d_ 4 alkyl) and -N(C 1 . 4 alkyl) 2 ;
- R 5 is selected from
- R 1b , R 2b , and R 3b are independently hydrogen, hydroxy, CN, (C C 4 )alkyl, (C C 4 )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 -membered heterocyclyl containing N, O or S as a ring member, wherein each (Ci-C )alkyl, (Ci-C )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 -membered heterocyclyl containing N, O or S as a ring member may be substituted with one, two or three substituents selected independently from Y,
- R 2b and R 3b together with the nitrogen atom to which they are bonded can optionally form a 5- to 7-membered heterocyclyl including 0 or 1 further heteroatoms selected from N, O and S, said heterocyclyl optionally substituted by Y;
- L 2 is independently at each occurrence a bond or a straight chain or branched Ci_ alkylene, optionally substituted with NH 2 , OH, or F;
- Het is optionally fused to a 5 or 6 membered heterocyclic or heteroaryl ring containing up to two heteroatoms selected from N-R 10 , O and S as ring members, and optionally substituted with one or two R 16 ;
- R 10 and R 12 are independently H or Ci_ alkyl optionally substituted by one or two groups selected from OH, NH 2 or Q;
- each Cy is independently a 3-6 membered cycloalkyi or 3-6 membered heterocyclyl containing one or two heteroatoms selected from N, O and S as a ring member and optionally fused to a 5-6 membered aryl or heteroaryl ring, wherein each Cy is optionally substituted with one or two groups selected from halo, Ci_ 3 haloalkyl, R 14 , hydroxy, Ci_ 4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) or -N(d_ 4 alkyl) 2 ;
- Ar is phenyl, optionally substituted with one or two groups selected from halo, Ci_ 3 haloalkyl, R 14 , hydroxy, d_ 4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) or -N(d_ 4 alkyl) 2 ;
- R 11 is independently at each occurrence Ci_ 4 alkyl
- R 10 , or two R 11 , or two R 12 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with Ci_ 4 alkyl, Ci. alkoxy, hydroxy, or oxo;
- R 13 is independently at each occurrence H or Ci_ 4 alkyl optionally substituted with hydroxy, Ci_ 4 alkoxy, -NH 2 , -NH(Ci- 4 alkyl) or -N(Ci- 4 alkyl) 2 ;
- R 14 is independently at each occurrence C 1- alkyl optionally substituted with hydroxy, d_ 4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) or -N(d_ 4 alkyl) 2 ;
- R 15 is H, halo, d_ 4 alkyl, CN, or -0(d_ 4 alkyl);
- each R 16 is independently halo, Ci_ 4 alkyl, -NH 2 , CN, or -0(Ci. 4 alkyl);
- the invention provides a method of inhibiting bacterial growth or modulating the virulence of a bacterial infection, wherein the method comprises
- the invention provides a method for treating a subject having a Gram-negative bacterial infection, which comprises administering to the subject in need thereof an antibacterially effective amount of a compound of formula (I), optionally in combination with a pharmaceutically acceptable carrier.
- the subject is a mammal and in some embodiments, the subject is a human.
- the Gram-negative bacteria may be of a genus selected from Citrobacter,
- Pseudomonas Acinetobacter, Bacteroides, Burkholderia, Campylobacter, Neisseria, and Stenotrophomonas.
- a bacterial infection caused by a species of Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Proteus, Salmonella, Serratia,
- Pseudomonas, or Acinetobacter is treatable.
- Particular bacterial species for such treatment include Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter faecalis, Enterobacter faecium, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca,
- Pseudomonas aeruginosa and Acinetobacter baumanii, as well as Bacteroides bivius, Bacteroides fragilis, Burkholderia cepacia, Campylobacter jejuni, Neisseria gonorrhoeae, and Stenotrophomonas maltophilia.
- the invention provides a method of administering an inhibitory amount of a compound of formula (I) to fermenting or non-fermenting Gram-negative bacteria.
- the Gram- negative bacteria are species of Burkholderia, Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Neisseria, Proteus, Salmonella, Serratia, Pseudomonas, and Acinetobacter.
- Particular bacterial species for such methods include Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter faecalis, Enterobacter faecium, Escherichia coli, Klebsiella pneumonia, Klebsiella oxytoca, Neisseria meningiditis and Burkholderia cepacia, Morganella morganii, Proteus mirabilis, Salmonella species, Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumanii, as well as Bacteroides bivius, Bacteroides fragilis, Burkholderia cepacia, Campylobacter jejuni, Neisseria gonorrhoeae, and Stenotrophomonas maltophilia.
- the invention provides a method of administering an inhibitory amount of a compound of formula (I) to Gram-negative bacteria, such as an Enterobacteriaceae; in some embodiments the Gram-negative bacteria is selected from the group consisting of species of Citrobacter, Enterobacter, Escherichia, Klebsiella,
- Another embodiment of the invention provides a pharmaceutical composition comprising an effective amount of a compound of Formula (I) combined with a
- An 'effective amount' as used here refers to an amount sufficient to reduce the severity or symptoms of an infection, or an amount effective to reduce bacteria load in the patient.
- compositions according to the present invention are provided which include any of the compounds described herein and a pharmaceutically acceptable carrier.
- the composition includes an additional therapeutic agent or a beta lactamase inhibitor.
- the invention provides a pharmaceutical combination comprising a compound of the invention and an additional therapeutic agent or a beta lactamase inhibitor or optionally both.
- the present invention provides novel compounds, methods for inhibiting survival and population growth of Gram-negative bacteria, and novel methods and compositions for treating bacterial infections in mammals, particularly in human subjects.
- the compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in methods to inhibit bacterial growth or severity or duration of a bacterial infection, or to treat a subject having a bacterial infection that is susceptible to inhibition by the compounds of Formula (I).
- the invention also provides for the use of the compounds in preparing medicaments and pharmaceutical formulations, for use of the compounds in inhibiting bacterial growth, and for use of the compounds in treating bacterial infections in a subject in need of such treatment, e.g., a subject infected with a Gram-negative bacteria or at especially high risk for such infection.
- the term "subject" refers to an animal.
- the animal is a mammal.
- a subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- primates e.g., humans
- the subject is a human.
- the term “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process, or decrease in the viability, number or growth rate of a bacterial population.
- treating refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
- treating refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
- treating or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
- antibacterial agent refers to agents synthesized or modified in the laboratory that have either bactericidal or bacteriostatic activity.
- An "active” agent in this context will inhibit the growth of P. aeruginosa and / or other Gram-negative bacteria.
- the term “inhibiting the growth” indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced. Thus, the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated.
- Optionally substituted means the group referred to can be substituted at one or more positions by any one or any combination of the radicals listed thereafter. Such substitution involves the replacement of a hydrogen atom of the unsubstituted group with another moiety; thus the number of substituents that can be added to any unsubstituted group is equal to the number of hydrogen atoms on the unsubstituted group. If not otherwise specified, Optionally substituted' means that up to three non-hydrogen substituent groups can be added.
- Halo or "halogen”, as used herein, may be fluorine, chlorine, bromine or iodine.
- Ci-C 6 alkyl or “Ci_ 6 alkyl” as used herein, denotes straight chain or branched alkyl having 1-6 carbon atoms. If a different number of carbon atoms is specified, such as C 8 or C 3 , then the definition is to be interpreted accordingly, such as “CrC 4 alkyl” will include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
- C C 6 alkoxy denotes straight chain or branched alkoxy having 1-6 carbon atoms. If a different number of carbon atoms is specified, such as C 8 or C3, then the definition is to be interpreted accordingly, e.g., "C1-C4 alkoxy” will represent methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert- butoxy.
- C C4-Haloalkyl or "Ci_ 4 haloalkyl” as used herein, denotes straight chain or branched alkyl having 1-4 carbon atoms, wherein at least one hydrogen has been replaced by a halogen.
- Ci-C 4 -Haloalkyl will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with halogen, such as where the halogen is fluorine: CF 3 CF 2 -, (CF 3 )2CH-, CH 3 - CF2-, CF 3 CF 2 -, CF 3 , CF2H-, CF 3 CF 2 CHCF 3 or CF 3 CF 2 CF 2 CF2-.
- C 3 -C 8 -cycloalkyl or "C 3 . 8 cycloalkyl” as used herein refers to a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. If a different number of carbon atoms is specified, such as C 3 -C 6 , then the definition is to be interpreted accordingly.
- heterocyclyl and "5- to 14-membered heterocyclyl”, refer, respectively, to 4- to 8-membered, 5- to 6-membered, 3- to 10-membered, 3- to 14-membered, 4- to 14-membered and 5- to 14-membered heterocyclic rings containing 1 to 7, 1 to 5 or 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, which may be saturated, or partially saturated.
- heterocyclic may be used interchangeably with “heterocyclyl”.
- heterocyclic group can be attached at a heteroatom or a carbon atom.
- heterocyclyl includes single ring groups, fused ring groups and bridged groups.
- heterocyclyl include, but are not limited to pyrrolidine, piperidine, piperazine, oxazolidine, pyrrolidinone, morpholine, tetrahydrofuran, tetrahydrothiophene,
- a heterocyclic or heterocyclyl group is a saturated or partially saturated monocyclic group unless otherwise specified, and contains 5-7 ring atoms with up to two heteroatoms selected from N, O and S as ring members.
- a heterocyclic group further includes bicyclic ring systems containing 1 or 2 heteroatoms such as N, O or S as ring members and comprising two fused 3-, 4-, 5-, or 6-membered rings, such as 3- azabicyclo[3.1.0]hexane, 8-aza-bicyclo[3.2.1]octane, 3,8-diazabicyclo[3.2.1]octane, 3-Oxa-8- aza-bicyclo[3.2.1 ]octane, 8-Oxa-3-aza-bicyclo[3.2.1 ]octane, 2-Oxa-5-aza- bicyclo[2.2.1 ]heptane, 2,5-Diaza-bicyclo[2.2.1 ]heptane.
- Heteroaryl is a completely unsaturated (aromatic) ring.
- the term “heteroaryl” refers to a 5-14 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to 8 heteroatoms selected from N, O and S.
- the heteroaryl is a 5-10 membered ring system (e.g., 5-6 membered monocycle or an 8-10 membered bicycle) or a 5-6 membered ring system.
- a heteroaryl is preferably an isolated 5-6 membered ring containing up to 4 heteroatoms selected from N, O and S as ring members.
- Typical heteroaryl groups include furan, isothiazole, thiadiazole, oxadiazole, indazole, indole, quinoline, 2- or 3-thienyl; 2- or 3-furyl; 2- or 3-pyrrolyl; 1-, 2-, 4-, or 5-imidazolyl; 1 , 3-, 4-, or 5- pyrazolyl; 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5- isoxazolyl, 3- or 5-(1 ,2,4-triazolyl), 4- or 5-(1 ,2, 3-triazolyl), tetrazolyl, triazine, pyrimidine, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, or 5- pyrimidinyl.
- hydroxy refers to the group -OH, or when used as part of a group name such as hydroxyalkyl, it refers to the named group substituted with an -OH.
- hydroxyalkyl refers to the group substituted with an -OH.
- Z is CR 4 or N
- R 1 is H or C1-C4 alkyl
- R 2 is selected from the group consisting of H , C1-C4 alkyl, and -COOH
- R 1 and R 2 taken together with the carbon to which they are attached form a ring selected from a C 3 -C 6 cycloalkyi ring and a 4-6 membered heterocyclic ring containing up to two heteroatoms selected from N, O and S as ring members;
- R 3 is selected from H, -COOH, and -L 1 -W-(CH 2 ) 0 -2-X-R 5 ;
- R 4 is H or halo
- each L 1 is independently a straight chain or branched Ci_ 4 alkylene
- W is a bond, O, NH or S
- X is phenyl, or a 5-6 membered heteroaryl ring containing 1 -3 heteroatoms selected from N, O and S as ring members; where the phenyl and 5-6 membered heteroaryl are optionally substituted with one or two groups selected from Ci_ 4 alkyl, hydroxy, -CN , F, Ci_ 4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) and -N(C 1 . 4 alkyl) 2 ;
- R 5 is selected from
- R 1 b , R 2b , and R 3b are independently hydrogen, hydroxy, CN, (C C 4 )alkyl, (C C 4 )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 -membered heterocyclyl containing N, O or S as a ring member, wherein each (Ci-C )alkyl, (Ci-C )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 -membered heterocyclyl containing N, O or S as a ring member may be substituted with one, two or three substituents selected independently from Y, and wherein R and R together with the nitrogen atom to which they are bonded can optionally form a 5- to 7-membered heterocyclyl including 0 or 1 further heteroatoms selected from N, O and S, said heterocyclyl optionally substituted by Y;
- L 2 is independently at each occurrence a bond or a straight chain or branched Ci_ alkylene, optionally substituted with NH 2 , OH, or F;
- Het is optionally fused to a 5 or 6 membered heterocyclic or heteroaryl ring containing up to two heteroatoms selected from N-R 10 , O and S as ring members, and optionally substituted with one or two R 16 ;
- R 10 and R 12 are independently H or C1-4 alkyl optionally substituted by one or two groups selected from OH, NH 2 or Q;
- each Cy is independently a 3-6 membered cycloalkyl or 3-6 membered heterocyclyl containing one or two heteroatoms selected from N, O and S as a ring member and optionally fused to a 5-6 membered aryl or heteroaryl ring, wherein each Cy is optionally substituted with one or two groups selected from halo, C1.3 haloalkyl, R 14 , hydroxy, C1.4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) or -N(d.
- Ar is phenyl, optionally substituted with one or two groups selected from halo, Ci_ 3 haloalkyl, R 14 , hydroxy, d- 4 alkoxy, -NH 2 , -NH(Ci_4 alkyl) or -N(C 1 . 4 alkyl) 2 ;
- R 11 is independently at each occurrence Ci_ 4 alkyl
- R 10 , or two R 11 , or two R 12 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with Ci_ 4 alkyl, Ci_ 4 alkoxy, hydroxy, or oxo;
- R 13 is independently at each occurrence H or Ci_ 4 alkyl optionally substituted with hydroxy, Ci_ 4 alkoxy, -NH 2 , -NH(Ci_ alkyl) or -N(Ci_ alkyl) 2 ; optionally, when R 13 is C 1-4 alkyl it can be substituted with -OR 14 , -NHR 14 , hydroxy, d- 4 alkoxy, -NH 2 , -NH(d- 4 alkyl) or - N(d. 4 alkyl) 2 ;
- R 14 is independently at each occurrence C 1-4 alkyl optionally substituted with hydroxy, d-4 alkoxy, -NH 2 , -NH(Ci- 4 alkyl) or -N(d- 4 alkyl ) 2 ;
- R 13 or two R 14 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with Ci_ 4 alkyl, d_ 4 alkoxy, hydroxy, amino or oxo;
- R 15 is H, halo, d_ 4 alkyl, CN, or -0(d_ 4 alkyl);
- each R 16 is independently halo, Ci_ 4 alkyl, -NH 2 , CN, or -0(d_ 4 alkyl);
- Z is CR 4 or N
- R 1 is H or d-d alkyl
- R 2 is selected from the group consisting of H, d-d alkyl, and -COOH
- R 1 and R 2 taken together with the carbon to which they are attached form a ring selected from a -d cycloalkyi ring and a 4-6 membered heterocyclic ring containing up to two heteroatoms selected from N, O and S as ring members;
- R 3 is selected from H, -COOH, and -L 1 -W-(CH 2 ) 0 - 2 -X-R 5 ;
- R 4 is H or halo
- each L 1 is independently a straight chain or branched Ci_ 4 alkylene
- W is a bond, O, NH or S
- X is phenyl, or a 5-6 membered heteroaryl ring containing 1 -3 heteroatoms selected from N, O and S as ring members; where the phenyl and 5-6 membered heteroaryl are optionally substituted with one or two groups selected from Ci_ alkyl, hydroxy, -CN, F, Ci_ alkoxy, -NH 2 , -NH(Ci_4 alkyl) and -N(C 1 . 4 alkyl) 2 ;
- R 5 is selected from
- R 1b , R 2b , and R 3b are independently hydrogen, hydroxy, CN, (Ci- C 4 )alkyl, (C C 4 )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 -membered heterocyclyl, wherein each (C C 4 )alkyl, (C C 4 )alkoxy, (C 3 -C 6 )cycloalkyl, or 4-, 5-, 6- or 7 - membered heterocyclyl may be substituted with one, two or three substituents selected independently from Y,
- R 2b and R 3b together with the nitrogen atom to which they are bonded can optionally form a 5- to 7-membered heterocyclyl including 0 or 1 further heteroatoms selected from N, O and S, said heterocyclyl optionally substituted by Y;
- L 2 is independently at each occurrence a bond or a straight chain or branched Ci_ alkylene
- Het is optionally fused to a 5 or 6 membered heterocyclic or heteroaryl ring containing up to two heteroatoms selected from N, O and S as ring members, and optionally substituted with one or two R 16 ;
- R 10 and R 12 are independently H or Ci_ alkyl optionally substituted by Q;
- R 11 is independently at each occurrence Ci_ 4 alkyl
- R 10 , or two R 11 , or two R 12 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with Ci_ 4 alkyl, Ci_ 4 alkoxy, hydroxy, or oxo;
- R 13 is independently at each occurrence H or Ci_ 4 alkyl optionally substituted with hydroxy, Ci- 4 alkoxy, -NH 2 , -NH(Ci- 4 alkyl) or -N(Ci_ 4 alkyl) 2 ;
- R 14 is independently at each occurrence C 1-4 alkyl optionally substituted with hydroxy, d_ 4 alkoxy, -NH 2 , -NH(d_ 4 alkyl) or -N(d_ 4 alkyl) 2 ;
- R 13 or two R 14 on the same N can cyclize to form a 4-6 membered heterocyclic ring optionally substituted with Ci -4 alkyl, Ci_ alkoxy, hydroxy, amino or oxo;
- R 15 is H, halo, d_ 4 alkyl, CN, or -0(d_ 4 alkyl);
- each R 16 is independently halo, Ci_ 4 alkyl, -NH 2 , CN, or -0(d_ 4 alkyl);
- Het is a 5- membered heteroaryl ring containing 1-4 nitrogen atoms as ring members and is optionally substituted with Y.
- Het is triazole optionally substituted with Y.
- R 17 is selected from -CH 2 -G 1 -(CH 2 )i- 4 -G 2 and -CH 2 -G 1 -R x -(CH 2 ) 0 - 2 -G 2
- R x is a ring selected from cyclobutyl, azetidine, and pyrrolidine.
- Het is selected from pyrrolidine-2- one, oxazolidin-2-one, and imidazolidin-2-one, and is optionally substituted with Y.
- Het is selected from:
- Y is of the formula -L 2 -NR 10 -L 2 -N(R 10 ) 2
- Y can be a group such as -CH 2 -NR 10 -(CH2)2-3-N(R 10 ) 2 ; in particular embodiments of these compounds, R 10 is H.
- R is selected from H, azetidine, pyrrolidine and piperidine.
- a pharmaceutical composition comprising a compound of any of the preceding embodiments and at least one pharmaceutically acceptable excipient.
- a method to treat a Gram-negative bacterial infection which comprises
- bacterial infection is caused by a species of Burkholderia, Citrobacter, Enterobacter, Escherichia, Klebsiella, Meningitidis, Morganella, Pseudomonas, Proteus, Salmonella, Serratia, Acinetobacter, Bacteroides, Campylobacter, Neisseria, or Stenotrophomonas bacteria.
- a compound according to any of embodiments 1-27 for use as a medicament for use as a medicament.
- the antibacterial agent is for treatment of a Gram-negative bacterial infection caused by a species of Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Pseudomonas, Proteus, Salmonella, Serratia, Acinetobacter, Bacteroides, Burkholderia, Campylobacter, Neisseria, or Stenotrophomonas.
- a pharmaceutical combination comprising a compound according to any of embodiments 1-27 and a second therapeutic agent.
- the oxime is preferably of the configuration shown here:
- R 2 and R 3 represent -COOH.
- Het is not pyridine.
- Het is a 5-membered heteroaryl or heterocyclic ring.
- R 3 in any of the above embodiments is of the formula -L 1 -W-(CH 2 )o-2-X-R 5 , can be phenyl.
- L 1 is CH 2 .
- W is O.
- R 5 is a group of the formula
- R 1 b , R 2b and R 3b are as described for embodiment 1 above.
- R 5 is of the formula wherein R 1 b and R 2b each represent H, and R 3b can be H,or a heterocyclic group such as 4-piperidinyl.
- R 1 is H and R 2 is H or COOH.
- the invention provides:
- a pharmaceutical combination comprising (a) a first therapeutic agent which is a compound of the invention, e.g. a compound of formula (I) or any subformula thereof described herein, and (b) a second therapeutic agent as described above.
- a method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a compound of the invention, e.g. a compound of formula (I) or any subformulae thereof that is described herein, and a second therapeutic agent as described above.
- co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. Fixed combinations are also within the scope of the present invention.
- the administration of a pharmaceutical combination of the invention results in a beneficial effect, e.g. a synergistic therapeutic effect, compared to a monotherapy applying only one of its pharmaceutically active ingredients.
- Each component of a combination according to this invention may be administered separately, together, or in any combination thereof.
- the compound of the invention and any additional agent may be formulated in separate dosage forms. Alternatively, to decrease the number of dosage forms
- the compound of the invention and any additional agent may be formulated together in any combination.
- the compound of the invention inhibitor may be formulated in one dosage form and the additional agent may be formulated together in another dosage form.
- Any separate dosage forms may be administered at the same time or different times.
- composition of this invention comprises an additional agent as described herein.
- Each component may be present in individual compositions, combination compositions, or in a single composition.
- the compounds of the invention may be synthesized by the general synthetic routes below, specific examples of which are described in more detail in the Examples.
- protecting group a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention.
- the protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J.
- Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art.
- salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
- metal compounds such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid
- organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbonates
- Acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent.
- Internal salts of compounds of the present invention containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
- Salts can be converted into the free compounds in accordance with methods known to those skilled in the art.
- Metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
- Mixtures of isomers obtainable according to the invention can generally be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
- Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
- All process steps for making compounds of the invention can be carried out under reaction conditions that are known to those skilled in the art, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g.
- mixtures of isomers that are formed can be separated into the individual isomers, for example diastereo isomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers
- solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2- one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride,
- the compounds of the present invention may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
- optical isomer or "a stereoisomer” refers to any of the various components
- stereoisomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
- the term "chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound.
- Enantiomers are a pair of stereoisomers that are non- superimposable mirror images of each other.
- a 1 :1 mixture of a pair of enantiomers is a "racemic” mixture.
- the term is used to designate a racemic mixture where appropriate.
- “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
- Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
- Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
- the present invention is meant to include all such possible stereoisomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
- Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
- a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0, 0 -p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
- Racemic products can also be resolved by chiral
- HPLC high pressure liquid chromatography
- the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their
- solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
- solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
- hydrate refers to the complex where the solvent molecule is water.
- the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
- salt refers to an acid addition or base addition salt of a compound of the present invention.
- Salts include in particular “pharmaceutically acceptable salts”.
- pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
- the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen
- Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
- the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
- Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
- the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
- any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds of the present invention.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 l respectively.
- the invention includes various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
- isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- an 18 F labeled compound of the present invention may be particularly desirable for PET or SPECT studies.
- Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
- a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
- solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, d 6 -acetone, d 6 -DMSO.
- co-crystals may be capable of forming co-crystals with suitable co- crystal formers.
- These co-crystals may be prepared from compounds of the present invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the present invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
- Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of the present invention.
- the present invention provides novel compounds, pharmaceutical formulations including the compounds, and methods of treating Gram-negative bacterial infections.
- the compounds are suitable for use to treat infections caused by Burkholderia, Citrobacter, Enterobacter, Escherichia, Klebsiella, Meningitidis, Morganella, Pseudomonas, Proteus, Salmonella, Serratia, Acinetobacter, Bacteroides, Campylobacter, Neisseria, or Stenotrophomonas bacteria, including species named herein.
- substitution with heavier isotopes such as deuterium, i.e. 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- deuterium substitution at non-exchangeable hydrocarbon bonds e.g., C-H
- Isotopically-labeled compounds of the invention i.e. compounds of formula (I)
- compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations Sections using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously.
- the invention provides a method for treating a subject with a Gram-negative bacterial infection, the method comprising the step of administering to the subject in need thereof an antibacterially effective amount of a compound of the invention, e.g., a compound of Formula I or salt thereof with a pharmaceutically acceptable carrier.
- a compound of the invention e.g., a compound of Formula I or salt thereof with a pharmaceutically acceptable carrier.
- the compounds of the invention also are useful in the treatment of patients suffering from or susceptible to pneumonia, sepsis, cystic fibrosis, wound, complicated diabetic foot or complicated urinary tract infections and sexually transmitted diseases caused by Gram- negative pathogens.
- the compounds of the invention also are useful in the conditions that are caused by a species of Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Proteus, Salmonella, Serratia, Pseudomonas, Acinetobacter, Bacteroides, Burkholderia, Campylobacter, Neisseria, or Stenotrophomonas.
- a bacterial infection caused by a species of Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Proteus, Salmonella, Serratia, Pseudomonas, or Acinetobacter is treatable by methods herein.
- Particular bacterial species for such treatment include Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Enterobacter faecalis, Enterobacter faecium, Escherichia coli, Klebsiella pneumonia, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis,
- Salmonella species Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumanii, as well as Bacteroides bivius, Bacteroides fragilis, Burkholderia cepacia,
- Campylobacter jejuni, Neisseria gonorrhoeae, and Stenotrophomonas maltophilia Campylobacter jejuni, Neisseria gonorrhoeae, and Stenotrophomonas maltophilia.
- a compound of the present invention may also be used in combination with other agents, e.g., an additional antibiotic agent that is or is not of the formula I, for treatment of a bacterial infection in a subject, or a compound that enhances the antibacterial activity of the compounds of the invention, including potentiators such as beta-lactamase inhibitors (BLIs).
- additional antibiotic agent that is or is not of the formula I
- BBIs beta-lactamase inhibitors
- Suitable BLIs for use in combination with the compounds of the invention include avibactam, clavulanic acid, sulbactam, tazobactam, and other compounds of the formula wherein M is H or a pharmaceutically acceptable cation, and R represents CN, - C(0)NR 1 R 2 , or an optionally substituted 5-6 membered heterocyclic or heteroaryl group.
- Suitable amides include those where R 1 is H or Ci_ alkyl, and R 2 is optionally substituted Ci_ alkyl, optionally substituted Ci_ 4 alkoxy, optionally substituted Ci_ 4 alkylamino, an optionally substituted C 5 -6 heterocyclic group, or -NH-C(0)-R 3 , where R 3 is optionally substituted Ci -4 alkyl, optionally substituted Ci_ alkoxy, optionally substituted Ci_ alkylamino, an optionally substituted C 5 -6 heterocyclic group.
- Each heterocyclic or heteroaryl group in these compounds contains 1-2 heteroatoms selected from N, O and S as ring members, and each optionally substituted group can be substituted by 1-2 groups selected from CN, halo, -OH, C-i-4 alkyl, Ci_ alkoxy, amino, Ci_ alkylamino, di(Ci_ alkyl)amino, -COO(Ci_ alkyl), and 5-6 membered heterocyclic groups.
- Suitable compounds of this formula are described in WO2008/039420, WO2009/091856, WO2013/122888, WO2010/126820, WO2009/091856, WO2013/038330, US2013/0225554, WO2013149121 , WO2013149136, WO2014141 132 and WO2014/033560.
- combination is meant either a fixed combination in one dosage unit form, or a kit or instructions for the combined administration where a compound of the present invention and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g., synergistic, effect, or any combination thereof.
- An embodiment of the present invention provides compounds of the present invention in a pharmaceutical combination with a second therapeutic agent.
- the second therapeutic agent is an antibacterial agent.
- antibacterial agents for use in pharmaceutical combinations of the invention may be selected from the following groups:
- Beta-lactams including penicillin such as penicillin G, penicillin V, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, azlocillin, temocillin, cephalosporin such as cepalothin, cephapirin, cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin, cefinetazole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, and carbapenems such as doripenem
- Glycopeptides such as vancomycin and teicoplanin
- Quinolones such asnalidixic acid, oxolinic acid, norfloxacin, pefloxacin, enoxacin, ofloxacin, levofloxacin, ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin, gatifloxacin, moxifloxacin, sitafloxacin,
- Antibacterial sulfonamides and antibacterial sulphanilamides including para- aminobenzoic acid, sulfadiazine, sulfisoxazole, sulfamethoxazole and sulfathalidine;
- Aminoglycosides such as streptomycin, neomycin, kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin, spectinomycin, sisomicin, dibekalin and isepamicin;
- Tetracyclines such as tetracycline, chlortetracycline, demeclocycline, minocycline, oxytetracycline, methacycline, doxycycline, tigecycline;
- Rifamycins such as rifampicin (also called rifampin), rifapentine, rifabutin, bezoxazinorifamycin and rifaximin;
- Lincosamides such as lincomycin and clindamycin
- Beta-lactamase inhibitors including avibactam and analogs thereof, and those described above.
- the second antibacterial agent may be administered in combination with the compounds of the present inventions wherein the second antibacterial agent is administered prior to, simultaneously, or after the compound or compounds of the present invention.
- a compound of the invention may be formulated with a second agent into the same dosage form.
- An example of a dosage form containing a compound of the invention and a second agent is an intravenous
- An alternative example is an intramuscular adiministration of a solution comprising a compound of the invention and a second agent.
- the compounds and compositions described herein can be used or administered in combination with one or more therapeutic agents that act as immunomodulators, e.g., an activator of a costimulatory molecule, or an inhibitor of an immune-inhibitory molecule, or a vaccine.
- the Programmed Death 1 (PD-1 ) protein is an inhibitory member of the extended CD28/CTLA4 family of T cell regulators (Okazaki et al. (2002) Curr Opin Immunol 14:
- PD-1 is expressed on activated B cells, T cells, and monocytes.
- PD-1 is an immune-inhibitory protein that negatively regulates TCR signals (Ishida, Y. et al. (1992) EMBO J. 1 1 :3887-3895; Blank, C. et al. (Epub 2006 Dec. 29) Immunol. Immunother. 56(5):739-745), and is up-regulated in chronic infections.
- the interaction between PD-1 and PD-L1 can act as an immune checkpoint, which can lead to, e.g., a decrease in infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and/or immune evasion by cancerous or infected cells (Dong et al. (2003) J. Mol. Med. 81 :281-7; Blank et al. (2005) Cancer Immunol. Immunother. 54:307-314; Konishi et al. (2004) Clin. Cancer Res. 10:5094-100).
- Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1 or PD-L2; the effect is additive when the interaction of PD-1 with PD-L2 is blocked as well (Iwai et al. (2002) Proc. Nat'l. Acad. Sci. USA 99:12293-7; Brown et al. (2003) J. Immunol. 170:1257-66).
- Immunomodulation can be achieved by binding to either the immune-inhibitory protein (e.g., PD-1 ) or to binding proteins that modulate the inhibitory protein (e.g., PD-L1 , PD-L2).
- the combination therapies of the invention include an immunomodulator that is an inhibitor or antagonist of an inhibitory molecule of an immune checkpoint molecule.
- the immunomodulator binds to a protein that naturally inhibits the immuno-inhibitory checkpoint molecule.
- these immunomodulators can enhance the antimicrobial response, and thus enhance efficacy relative to treatment with the antibacterial compound alone.
- Immune checkpoints refers to a group of molecules on the cell surface of CD4 and CD8 T cells. These molecules can effectively serve as “brakes” to down-modulate or inhibit an adaptive immune response. Immune checkpoint molecules include, but are not limited to, Programmed Death 1 (PD-1 ), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), B7H1 , B7H4, OX-40, CD137, CD40, and LAG 3, which directly inhibit immune cells.
- PD-1 Programmed Death 1
- CTL-4 Cytotoxic T-Lymphocyte Antigen 4
- B7H1 B7H4, OX-40
- CD137 CD40
- LAG 3 which directly inhibit immune cells.
- Immunotherapeutic agents which can act as immune checkpoint inhibitors useful in the methods of the present invention, include, but are not limited to, inhibitors of PD-L1 , PD-L2, CTLA4, TIM3, LAG 3, VISTA, BTLA, TIGIT, LAIR1 , CD160, 2B4 and/or TGFR
- Inhibition of an inhibitory molecule can be performed by inhibition at the DNA, RNA or protein level.
- an inhibitory nucleic acid e.g., a dsRNA, siRNA or shRNA
- the inhibitor of an inhibitory signal is a polypeptide, e.g., a soluble ligand, or an antibody or antigen-binding fragment thereof, that binds to the inhibitory molecule.
- immunomodulator can be administered concurrently with, prior to, or subsequent to, one or more compounds of the invention, and optionally one or more additional therapies or therapeutic agents.
- the therapeutic agents in the combination can be administered in any order. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. It will further be appreciated that the therapeutic agents utilized in this combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that each of the therapeutic agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
- the antibacterial compounds described herein are administered in combination with one or more immunomodulators that are inhibitors of PD-1 , PD-L1 and/or PD-L2.
- Each such inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide. Examples of such immunomodulators are known in the art.
- the immunomodulator is an anti-PD-1 antibody chosen from MDX-1 106, Merck 3475 or CT- 01 1 .
- the immunomodulator is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PD-LI or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence).
- an immunoadhesin e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PD-LI or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence).
- the immunomodulator is a PD-1 inhibitor such as AMP-224.
- the immunomodulator is a PD-LI inhibitor such as anti- PD-LI antibody.
- the immunomodulator is an anti-PD-LI binding antagonist chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1 105.
- MDX-1 105 also known as BMS-936559, is an anti-PD-LI antibody described in
- Antibody YW243.55.S70 is an anti-PD-LI described in WO 2010/077634.
- the immunomodulator is nivolumab (CAS Registry Number: 946414-94-4).
- Alternative names for nivolumab include MDX-1 106, MDX-1 106-04, ONO- 4538, or BMS-936558.
- Nivolumab is a fully human lgG4 monoclonal antibody which specifically blocks PD-1 .
- Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are disclosed in US 8,008,449, EP2161336 and
- the immunomodulator is an anti-PD-1 antibody
- Pembrolizumab is a humanized lgG4 monoclonal antibody that binds to PD-1 .
- Pembrolizumab and other humanized anti-PD-1 antibodies are disclosed in Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134-44, US 8,354,509,
- the immunomodulator is Pidilizumab (CT-01 1 ; Cure Tech), a humanized lgG1 k monoclonal antibody that binds to PD1 .
- Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/10161 1 .
- Other anti-PD1 antibodies useful as immunomodulators for use in the methods disclosed herein include AMP 514 (Amplimmune), and anti-PD1 antibodies disclosed in US 8,609,089, US 2010028330, and/or US 201201 14649.
- the anti-PD- L1 antibody is MSB0010718C.
- MSB0010718C also referred to as A09-246-2; Merck Serono
- the immunomodulator is MDPL3280A (Genentech / Roche), a human Fc optimized lgG1 monoclonal antibody that binds to PD-L1 .
- MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S Publication No. : 20120039906.
- Other anti-PD-L1 binding agents useful as immunomodulators for methods of the invention include YW243.55.S70 (see
- WO2010/077634 MDX-1 105 (also referred to as BMS-936559), and anti-PD-L1 binding agents disclosed in WO2007/005874.
- the immunomodulator is AMP-224 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO201 1/066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD1 and B7-H1 .
- the immunomodulator is an anti-LAG-3 antibody such as BMS-986016.
- BMS-986016 (also referred to as BMS986016) is a monoclonal antibody that binds to LAG-3.
- BMS-986016 and other humanized anti-LAG-3 antibodies are disclosed in US 201 1/0150892, WO2010/019570, and WO2014/008218
- the combination therapies disclosed herein include a modulator of a costimulatory molecule or an inhibitory molecule, e.g., a co-inhibitory ligand or receptor.
- the costimulatory modulator, e.g., agonist, of a costimulatory molecule is chosen from an agonist (e.g., an agonistic antibody or antigen-binding fragment thereof, or soluble fusion) of OX40, CD2, CD27, CDS, ICAM-1 , LFA-1 (CD1 1 a/CD18), ICOS (CD278), 4-1 BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.
- an agonist e.g., an agonistic antibody or antigen-binding fragment thereof, or soluble fusion
- OX40 e.g., CD2, CD27, CDS, ICAM-1 , LFA-1 (CD1 1 a/CD18), ICOS (CD278), 4-1 BB (CD137), GITR, CD30, CD40, BAF
- the combination therapies disclosed herein include an immunomodulator that is a costimulatory molecule, e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and/or GITR.
- an immunomodulator that is a costimulatory molecule, e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and/or GITR.
- Exemplary GITR agonists include, e.g., GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as, a GITR fusion protein described in U.S. Patent No.: 6, 1 1 1 ,090, European Patent No.: 090505B1 , U.S Patent No.: 8,586,023, PCT Publication Nos.: WO 2010/0031 18 and 201 1/090754, or an anti-GITR antibody described, e.g., in U.S. Patent No.: 7,025,962, European Patent No.: 1947183B1 , U.S. Patent No.: 7,812, 135, U.S. Patent No.: 8,388,967, U.S.
- anti-GITR antibodies e.g., bivalent anti-GITR antibodies
- the immunomodulator used is a soluble ligand (e.g., a CTLA-4- Ig), or an antibody or antibody fragment that binds to PD-L1 , PD-L2 or CTLA4.
- a soluble ligand e.g., a CTLA-4- Ig
- the anti-PD-1 antibody molecule can be administered in combination with an anti-CTLA-4 antibody, e.g., ipilimumab, for example.
- anti-CTLA4 antibodies include
- Tremelimumab (lgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206); and Ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9).
- an anti-PD-1 antibody molecule is administered after treatment with a compound of the invention as described herein.
- an anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody or an antigen-binding fragment thereof.
- the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-TIM-3 antibody or antigen-binding fragment thereof.
- the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody and an anti-TIM-3 antibody, or antigen-binding fragments thereof.
- the combination of antibodies recited herein can be administered separately, e.g., as separate antibodies, or linked, e.g., as a bispecific or trispecific antibody molecule.
- a bispecific antibody that includes an anti-PD-1 or PD-L1 antibody molecule and an anti-TIM-3 or anti- LAG-3 antibody, or antigen-binding fragment thereof is administered.
- the combination of antibodies recited herein is used to treat a cancer, e.g., a cancer as described herein (e.g., a solid tumor).
- a cancer e.g., a cancer as described herein (e.g., a solid tumor).
- the efficacy of the aforesaid combinations can be tested in animal models known in the art. For example, the animal models to test the synergistic effect of anti-PD-1 and anti-LAG-3 are described, e.g., in Woo et al. (2012) Cancer Res. 72(4):917-27).
- immunomodulators that can be used in the combination therapies include, but are not limited to, e.g., afutuzumab (available from Roche®); pegfilgrastim (Neulasta®); lenalidomide (CC-5013, Revlimid®); thalidomide (Thalomid®), actimid
- cytokines e.g., IL-21 or IRX-2 (mixture of human cytokines including interleukin 1 , interleukin 2, and interferon ⁇ , CAS 951209-71 -5, available from IRX
- Exemplary doses of such immunomodulators that can be used in combination with the antibacterial compounds of the invention include a dose of anti-PD-1 antibody molecule of about 1 to 10 mg/kg, e.g., 3 mg/kg, and a dose of an anti-CTLA-4 antibody, e.g., ipilimumab, of about 3 mg/kg.
- a method to treat a bacterial infection in a subject comprising administering to the subject a compound of Formula (I) as described herein, and an immunomodulator.
- the activator of the costimulatory molecule is an agonist of one or more of OX40, CD2, CD27, CDS, ICAM-1 , LFA-1 (CD1 1 a/CD18), ICOS (CD278), 4-1 BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 and CD83 ligand.
- inhibitor of the immune checkpoint molecule is chosen from PD-1 , PD-L1 , PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1 , CD160, 2B4 and TGFR beta.
- any of embodiments i-vii wherein the antibody or antigen-binding fragment thereof is altered, e.g., mutated, to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function.
- immunomodulator is an anti- PD-L1 antibody chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1 105.
- xii The method of any of embodiments i-x, wherein the immunomodulator is an anti- LAG-3 antibody molecule. xiii. The method of embodiment xii, wherein the anti-LAG-3 antibody molecule is BMS-986016,
- the immunomodulator is an anti- PD-1 antibody molecule administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg., e.g., once a week to once every 2, 3, or 4 weeks.
- xvi. The method of embodiment xv, wherein the anti-PD-1 antibody molecule, e.g., nivolumab, is administered intravenously at a dose from about 1 mg/kg to 3 mg/kg, e.g., about 1 mg/kg, 2 mg/kg or 3 mg/kg, every two weeks.
- the anti-PD-1 antibody molecule e.g., nivolumab
- xvii The method of embodiment xv, wherein the anti-PD-1 antibody molecule, e.g., nivolumab, is administered intravenously at a dose of about 2 mg/kg at 3-week intervals.
- the anti-PD-1 antibody molecule e.g., nivolumab
- an effective amount of the compound is that amount necessary or sufficient to treat or prevent a bacterial infection and/or a disease or condition described herein.
- an effective amount of the compound is an amount sufficient to treat bacterial infection in a subject.
- an effective amount of the compound is an amount sufficient to treat a bacterial infection, such as, but not limited to Pseudomonas aeruginosa and the like in a subject.
- the effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular compound of the invention. For example, the choice of the compound of the invention can affect what constitutes an "effective amount.”
- One of ordinary skill in the art would be able to study the factors contained herein and make the determination regarding the effective amount of the compounds of the invention without undue experimentation.
- the regimen of administration can affect what constitutes an effective amount.
- the compound of the invention can be administered to the subject either prior to or after the onset of a bacterial infection.
- the compound is administered to a subject diagnosed as having a bacterial infection and in need of treatment therefor.
- several divided dosages, as well as staggered dosages can be administered daily or sequentially, or the dose can be continuously infused, or can be a bolus injection.
- the dosages of the compound(s) of the invention can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
- the compound of the invention would be administered over a course of at least 5 days, more commonly at least 7 days or at least 10 days or at least 14 days.
- Compounds of the invention may be used in the treatment of states, disorders or diseases as described herein, or for the manufacture of pharmaceutical compositions for use in the treatment of these diseases.
- the invention provides methods of use of compounds of the present invention in the treatment of these diseases or pharmaceutical preparations having compounds of the present invention for the treatment of these diseases.
- composition includes preparations suitable for administration to mammals, e.g., humans.
- pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- phrases "pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals.
- the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'
- the pharmaceutical composition of the invention comprises a compound of any of the numbered embodiments and at least one pharmaceutically acceptable carrier or excipient. In certain embodiments, the pharmaceutical composition of the invention comprises a compound of any of the numbered embodiments and at least two pharmaceutically acceptable carriers or excipients.
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, - tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin,
- Formulations of the present invention include those suitable for oral, nasal, inhalation, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
- compounds of the invention would be administered intravenously, in the form of a solution that is often isotonic, such as a saline or glucose solution.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostea
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvants such as wetting agents,
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- various antibacterial and antifungal agents for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
- isotonic agents such as sugars, sodium chloride, and the like into the compositions.
- prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc., administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Intravenous administration is preferred.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a suitable daily dose of a compound of the invention will be that amount of the compound that is the dose effective to produce a therapeutic effect.
- Such an effective dose will generally depend upon the factors described above.
- intravenous and subcutaneous doses of the compounds of this invention for a patient when used for the indicated antibacterial effects, will range from about 5 to about 150 mg per kilogram of body weight per day, more preferably from about 15 to about 1 15 mg per kg per day, and still more preferably from about 20 to about 85 mg per kg per day.
- An effective amount is that amount treats a bacterial infection.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms, or as continuous infusion.
- a compound of the present invention While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
- the compounds as defined in embodiments may be synthesized by the general synthetic routes below, specific examples of which are described in more detail in the Examples.
- Heterocyclic intermediates A-2 could also be obtained as outlined in Scheme C, by alkylation of an amine such as C-1. Suitable alkylation reagents include alkyl halides or epoxides. Alkylation of C-1 could also be effected by reductive amination with an appropriately functionalized and protected aldehyde. Cyclization of C-2 could be effected using a carbonylating agent like CDI. Examples of the group Y in these compounds include oxygen or NR 5 , e.g., NH.
- the functionalized amines C-2 were alternatively obtained from B-1 by alkylation with a functionalized amine.
- a lactam heterocycle may analogously be obtained by alkylation of C-1 with brominated carboxylic esters, followed by base catalyzed cyclization.
- a heterocyde may be introduced to yield Intermediate A-2, by substitution of a leaving group in an appropriately protected azetidinone intermediate.
- Suitable protection groups include Cbz for the amine and DMB for the azetidinone. Deprotection of the Cbz group followed by acylation with appropriately functionalized and protected acids D-6 gave A-2, as outlined in Scheme D.
- D-1 Protected intermediates such as D-1 were also used for introduction of the heterocyde under Mitsunobu conditions, as outlined in Scheme A.
- D-1 was also converted to the corresponding azide, which was used for "click chemistry" to introduce 1 -linked 1 ,2,3 triazoles following a similar sequence as outlined in Scheme B.
- D-1 can also be used to yield functionalized amine derivatives that can be converted to heterocycles, as described in Scheme C.
- the invention is further illustrated by the following examples, which should not be construed as further limiting.
- the assays used throughout the Examples are accepted. Demonstration of efficacy in these assays is predictive of efficacy in subjects.
- Mass spectra were acquired on LC-MS, SFC-MS, or GC-MS systems using electrospray, chemical and electron impact ionization methods from a range of instruments of the following configurations: Waters ACQUITY UPLC system and equipped with a ZQ 2000 or SQD MS system where (M+1 ) refers to the protonated molecular ion of the chemical species, (M+) refers to the unprotonated quaternary ammonium cation, (M+Na) refers to the sodium-incorporated ion and (M-1 ) refers to the deprotonated molecular ion of the chemical species.
- NMR spectra were run on Bruker AVANCE 500MHz or Varian 400MHz NMR spectrometers using ICON-NMR, under TopSpin program control. Spectra were measured at 298K, unless indicated otherwise, and were referenced relative to the solvent resonance.
- Step 1 Benzyl ((2 ?,3S)-1-(2,4-dimethoxybenzyl)-2-(((2- hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)carbamate.
- Step 2 Benzyl ((3S,4 ?)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxooxazolidin-3- yl)methyl)azetidin-3-yl)carbamate.
- benzyl ((2R,3S)-1-(2,4- dimethoxybenzyl)-2-(((2-hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)carbamate (4.47g, 10.08 mmol) in chloroform (50 ml) was added CDI (4.90 g, 30.2 mmol). After stirring at rt for 30 min it was concentrated in vacuo.
- Step 3 Benzyl ((3S,4 ?)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)carbamate.
- step 2 using benzyl ((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)carbamate (3.84 g, 8.18 mmol), K 2 S 2 0 8 (3.10 g, 1 1.5 mmol) and K 2 HP0 4 (1.852 g, 10.6 mmol) in ACN:water (2:1 , 136 mL) while heating for 40 min at 90 °C.
- K 2 S 2 0 8 (663 g, 2.45 mmol) and K 2 HP0 4 (370 mg, 2.13 mmol) were added and it was heated for another 3 h. More K 2 S 2 0 8 (332 mg, 1.23 mmol) and K 2 HP0 4 (185 mg, 1.06 mmol) were added, and it was heated for an additional 2 h, whereupon it was concentrated in vacuo, removing most of the ACN. The mixture was diluted with brine/EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc (3x) and the combined orgnic layers were dried over Na 2 S0 4 .
- Step 4 3-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)oxazolidin-2-one.
- step 3 using benzyl ((3S,4R)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)azetidin-3-yl)carbamate (96 mg, 0.30 mmol) and Pd/C 10% Degussa type 101 (10%, 64 mg) in EtOH:MeOH (4:1 , 1.5 mL) for i h.
- the crude residue was used as such in following step.
- Step 1 (f?,E)-1-(2,4-dimethoxvphenvl)-N-((2,2-dimethyl-1 ,3-dioxolan-4- yl)methylene)methanamine.
- Step 2 2-g2S.3S)-1-(2.4-dimethoxvbenzvl)-2-(( ?)-2.2-dimethvl-1.3-dioxolan-4- yl)-4-oxoazetidin-3-yl)isoindoline-1 ,3-dione.
- 2-g2S.3S -1-(2.4-dimethoxvbenzvl)-2-(( ?)-2.2-dimethvl-1.3-dioxolan-4- yl)-4-oxoazetidin-3-yl)isoindoline-1 ,3-dione.
- Step 4 Benzyl ((2S,3S)-1 -(2,4-dimethoxybenzyl)-2-(( ?)-2,2-dimethyl-1 ,3- dioxolan-4-yl)-4-oxoazetidin-3-yl)carbamate.
- EtOAc benzyl chloroformate
- Step 5 Benzyl ((2S,3S)-2-(( ?)-1,2-dihydroxyethyl)-1-(2,4-dimethoxybenzyl)-4- oxoazetidin-3-yl)carbamate.
- benzyl ((2S,3S)-1-(2,4-dimethoxybenzyl)-2- ((R)-2,2-dimethyl-1 ,3-dioxolan-4-yl)-4-oxoazetidin-3-yl)carbamate (267 g, 0.567 mol) in THF (3 L) was added a solution of TsOH « H 2 0 (43.6 g, 0.229 mol) in water (0.75 L).
- Step 6 Benzyl ((2S,3S)-1 -(2,4-dimethoxybenzyl)-2-formyl-4-oxoazetidin-3- yl)carbamate.
- benzyl ((2S,3S)-2-((R)-1 ,2-dihydroxyethyl)-1-(2,4- dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate 240 g, 0.557 mol
- EtOAc 4.5 L
- a solution of sodium periodate 132 g, 0.617 mol
- the bilayer was heated to 50 °C for 2 h, whereupon it was cooled to rt and the layers were separated.
- Step 7 Benzyl ((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4- oxoazetidin-3-yl)carbamate.
- benzyl ((2S,3S)-1-(2,4-dimethoxybenzyl)-2- formyl-4-oxoazetidin-3-yl)carbamate (218 g, 0.546 mol) in a mixture of DCM:MeOH (4:1 , 2.25 L) at 0 °C was added sodium borohydride (41.3 g, 1.09 mol), portion-wise.
- Step 1 Benzyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate. Prepared according to Mastalerz et al. J. Med. Chem. 1988, 31, 1 190. To a solution of intermediate G (208 g, 0.529 mol) in ACN (4 L) was added potassium persulfate (243 g, 0.899 mol) followed by a solution of di potassium phosphate (147.4 g, 0.846 mol) in water (2 L). The resulting mixture was heated to 90 °C for 4 h then cooled to rt and concentrated in vacuo, removing most of the ACN.
- Step 2 (2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-amonium acetate.
- benzyl ((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate 25 g, 100 mmol
- MeOH 350 mL
- Pd on C 10% wet, 2.5 g
- AcOH 1 1.4 mL, 200 mmol
- the mixture was evacuated and recharged with H 2 (3x), bringing the final pressure to 50 psi. It was stirred at rt for 2 h, then discharged, filtered over celite and concentrated in vacuo, affording the crude title compound (22 g) as a light brown oil, which was used directly in step 3.
- Step 3 fert-Butyl 2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoate.
- Step 1 fert-Butyl 2-(((Z)-(1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2S,3S)-2-(iodomethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoate.
- Step 2 fert-Butyl 2-(((Z)-(2-(((2 ?,3S)-2-(azidomethyl)-4-oxoazetidin-3-yl)amino)- 1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoate.
- Step 1 2-Bromo-A -(prop-2-yn-1-yl)acetamide
- DCM dimethylethylamine
- a solution of propargylamine (0.57 g, 10.34 mmol) in DCM (10 mL) drop- wise over a period of 5 min, maintaining stirring throughout.
- the mixture was stirred at 0 °C for 2 h, whereupon the solids were filtered and the filtrate was concentrated in vacuo.
- Step 2 A,A,A -Trimethyl-2-oxo-2-(prop-2-yn-1 -ylamino)ethanaminium bromide.
- 2-bromo-/V-(prop-2-yn-1-yl)acetamide 0.6 g, 3.4 mmol
- trimethylamine 30% in MeOH, 5 mL
- Step 1 3-Methyl-4-((trimethylsilyl)ethynyl)pyridine.
- 4-bromo-3- methyl pyridine hydrochloride 5.0 g, 24.0 mmol
- THF degassed, 80 mL
- copper iodide 450 mg, 2.40 mmol
- triethylamine 20.0 mL, 143.9 mmol
- palladium tetrakis triphenylphosphine 830 mg, 0.72 mmol
- trimethylsilylacetylene (6.10 mL, 43.16 mmol) were added.
- Step 2 4-Ethynyl-3-methylpyridine. Prepared according to the method described in WO2013/028590. To a solution of 4-ethynyl-3-methylpyridine (3.79 g, 20 mmol) in THF (50 mL) was added TBAF (1 M in THF, 40 mL, 40 mmol). After stirring at rt for 1 h, the solution was concentrated in vacuo. The crude residue was purified via silica gel chromatography (EtOAc-Hexanes, 20-40%) affording the title compound (1.70 g, 72%) as an off white solid.
- Step 3 4-Ethynyl-1,3-dimethylpyridin-1-ium trifluoromethanesulfonate
- Step 1 Benzyl ((2S,3S)-1 -(2,4-dimethoxybenzyl)-2-(iodomethyl)-4-oxoazetidin-3- yl)carbamate.
- intermediate G 10 g, 25 mmol
- triphenylphosphine (19.6 g, 75 mmol) and imidazole (5.1 g, 75 mmol) in DCM (150 mL) at 0 °C was added iodine (19 g, 75 mmol) portion-wise over 10 min.
- Step 2 Benzyl ((2 ?,3S)-2-(azidomethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-
- Step 3 To a solution of benzyl ((2R,3S)-2-(azidomethyl)-1-(2,4-dimethoxybenzyl)-4- oxoazetidin-3-yl)carbamate (3.00 g, 7.06 mmol) in DCM (6 mL) was added DMSO: water: ferf-butanol (1 : 1 : 1 , 6 mL) ferf-butyl but-3-yn-1-ylcarbamate (2.19 g, 14.1 mmol), CuS0 4 (56 mg, 0.35 mmol) and sodium L-ascorbate (2.01 mg, 10.6 mmol).
- Step 1 The general procedure for the Mitsunobu reaction was followed. To a solution of intermediate G (5.00 g, 12.5 mmol), ferf-butyl ((2H-1 ,2,3-triazol-4- yl)methyl)carbamate (2.97 mg, 15.0 mmol), triphenylphosphine (3.93 mg, 15.0 mmol) and DIAD (3.0 mL, 15 mmol) in THF (100 mL). Purified via silica gel chromatography (MeOH- DCM, 2-5%), affording the title compound (12.6 g, contaminated with triphenylphosphine oxide) as a white foam.
- Step 2 To a solution of the product from step 1 (12.5 mmol) in ACN (150 mL) was added a solution of potassium persulfate (6.76 g, 25.0 mmol) and dipotassium phosphate (5.44 g, 31.2 mmol) in water (75 mL). The resulting mixture was heated to 90 °C for 4 h then cooled to rt, diluted with water and extracted with EtOAc. The organic layer was
- Step 1 Benzyl ((2f?,3S)-1 -(2,4-dimethoxybenzyl)-2-((1 ,3-dioxoisoindolin-2- yl)methyl)-4-oxoazetidin-3-yl)carbamate.
- the general procedure for the Mitsunobu reaction was followed using intermediate G (5.00 g, 12.5 mmol), phthalimide (1 .83 g, 12.5 mmol), triphenylphosphine (3.93 g, 15.0 mmol), DIAD (3.03 g, 15.0 mmol) and THF (150 mL). After stirring for 16 h, the formed precipitate was filtered, affording title compound (5.67 g, 85%) as a white solid.
- Step 2 Benzyl ((2 ?,3S)-2-(aminomethyl)-1 -(2,4-dimethoxybenzyl)-4-oxoazetidin-
- Step 3 To a solution of benzyl ((2R,3S)-2-(aminomethyl)-1 -(2,4-dimethoxybenzyl)-
- Step 4 To a solution of the product from step 3 (2.20 g, 3.85 mmol) in DCM (100 mL) at 0 °C was added CDI (1 .12 g, 6.92 mmol). After stirring at 15 °C for 2 h the solution was concentrated in vacuo. The crude residue was purified via silica gel chromatography (MeOH-DCM, 1 -5%) to afford the title compound (2.10 g, 91 %) as a white foam.
- Step 5 To a solution of the product from step 4 (2.10 g, 3.51 mmol) in ACN (40 ml.) was added a solution of potassium persulfate (1 .89 g, 7.02 mmol) and dipotassium phosphate (1.52 g, 8.75 mmol) in water (20 ml_). The resulting mixture was heated to 90 °C for 4 h then cooled to rt and filtered. The filtrate was concentrated, extracted with EtOAc and the organic layer was concntrated. The crude residue was purified via silica gel
- Step 1 (1 H-1,2,3-triazol-4-yl)methanol.
- DMF 160 mL
- MeOH 40 mL
- Cul 1.9 g, 10 mmol
- trimethylsilyl azide 34.6 g, 300 mmol
- Step 2 4-(((ferf-butyldimethvlsilvl)oxv)methyl)-1 H-1 ,2,3-triazole.
- (1 H-1 ,2,3-triazol-4-yl)methanol 30 g, 200 mmol
- DCM 160 mL
- imidazole 20.4 g, 300 mmol
- TBDMS-CI 33.3 g, 220 mmol
- Step 3 Benzyl ((2 ?,3S)-2-((4-(((ferf-butyldimethylsilyl)oxy)methyl)-2H-1 ,2,3- triazol-2-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate.
- Step 4 Benzyl ((2 ?,3S)-2-((4-(((ferf-butyldimethylsilyl)oxy)methyl)-2H-1 ,2,3- triazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbamate.
- Step 5 Benzyl ((2 ?,3S)-2-((4-(hydroxymethyl)-2H-1 ,2,3-triazol-2-yl)methyl)-4- oxoazetidin-3-yl)carbamate.
- Step 6 (3S,4f?)-3-amino-4-((4-(hvdroxvmethyl)-2H-1 ,2,3-triazol-2-yl)methyl)azetidin-2- one.
- benzyl ((2R,3S)-2-((4-(hydroxymethyl)-2H-1 ,2,3-triazol-2-yl)methyl)-4- oxoazetidin-3-yl)carbamate (1.54 g, 4.65 mmol) in EtOH (50 mL) and EtOH (25 mL) was added Pd/C (10%, 0.51 g, 4.65 mmol).
- Step 2 3-(acetamidomethyl)-1-methylpyridin-1-ium iodide
- Step 1 fert-Butyl 2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2- (((3S,4 ?)-2-oxo-4-((2-oxopyrrolidin-1-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 2 (3S,4R)-3-((Z)-2-(((1 -(iert-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)-2-(2- ((ieri-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxopyrrolidin-1 - yl)methyl)azetidine-1 -sulfonic acid.
- Step 3 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S.4 ?)-2-oxo-4-((2- oxopyrrolidin-1 -yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 2 2-(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 fert-Butyl 2-(((Z)-(1 -(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-(((2-((fer ⁇ utyldimethylsilyl)oxy)ethyl)amino)methyl)-4-oxoazetidin-3- yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 2 fert-Butyl 2-(((Z)-(1 -(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-(((2-hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 2 fert-Butyl 2-(((Z)-(1 -(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-(((2-hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 3 fert-Butyl 2-(((Z)-(1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2- (((3S,4 ?)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 3 fert-Butyl 2-(((Z)-(1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2- (((3S,4 ?)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 4 (3S,4 ?)-3-((Z)-2-(((1 -(fert-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxazolidin-3- yl)methyl)azetidine-1 -sulfonic acid.
- SteE_5 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 3 2-(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxoimidazolidin-1 -yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Ste l fert-Butyl 2-(((Z)-(2-(((2 ?,3S)-2-(((2-(((((9H-fluoren-9- yl)methoxy)carbonyl)amino)ethyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1 -(2-((fert- butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 2 fert-Butvl 2-(((Z)-(2-(((2 ?,3S)-2-(((2-aminoethyl)amino)methyl)-4- oxoazetidin-3-yl)amino)-1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 3 fert-Butyl 2-(((Z)-(1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2- (((3S,4 ?)-2-oxo-4-((2-oxoimidazolidin-1-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 4 (3S,4 ?)-3-((Z)-2-(((1 -(fert-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxoimidazolidin- 1-yl)methyl)azetidine-1-sulfonic acid.
- Step_5 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxoimidazolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 4 2-(((Z)-(2-(((2 ?,3S)-2-((5-(aminomethyl)-2H-tetrazol-2-yl)methyl)-4-oxo-1 - sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 A 75 mL pressure vessel was charged with Intermediate A (1 .50 g, 3.13 mmol), intermediate B (1 .108g, 4.70 mmol), K 2 C0 3 (1 .733 g, 12.54 mmol), Nal (564 mg, 3.76 mmol) and DMF (10 mL) then heated to 70 °C with stirring. After 3 h, more intermediate B (1 .108g, 4.70 mmol), K 2 C0 3 (1 .733 g, 12.54 mmol) and Nal (394 mg, 2.63 mmol) were added and heating was continued. After 8 h of total heating it was cooled to rt, diluted with EtOAc/brine and the layers were separated.
- Step 2 Prepared according to Mastalerz et al. J. Med. C em. 1988, 31, 1 190.
- K 2 S 2 0 8 (1 .40 g, 5.18 mmol
- K 2 HP0 4 837 mg, 4.81 mmol
- the resulting mixture was heated to 90 °C for 1.5 h, whereupon more K 2 S 2 0 8 (300 mg, 1.1 1 mmol) and K 2 HP0 4 (167 mg, 0.961 mmol) were added.
- Step 3 fert-Butyl ((2-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-tetrazol-5- yl)methyl)carbamate.
- a solution of compound from step 2 (785 mg, 1.819 mmol) in EtOAc:MeOH (5:1 , 65 mL) was evaculated and backfilled with argon (2x) followed by addition of Pd on C (10%, 581 mg). The system was evacuated and backfilled with H 2 (3x).
- Step 4 fert-Butvl 2-(((Z)-(2-(((2 ?,3S)-2-((5-(((fert-butoxycarbonyl)amino)methyl)- 2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 5 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((ferf- butoxycarbonyl)amino)methyl)-2H-tetrazol-2-yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 6 2-(((Z)-(2-(((2 ?.3S)-2-((5-(aminomethvl)-2tf-tetrazol-2-vl)methvl)-4-oxo-1 - sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 5 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((5-(guanidinomethyl)-2H- tetrazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 6 2-(((Z)-(2-(((2 ?,3S)-2-((5-(aminomethyl)-1 H-tetrazol-1 -yl)methyl)-4-oxo-1 - sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 Prepared in an analogous manner to Example 4, step 2 using the appropriate 1 H-tetrazole isomer obtained in Step 1 in Example 4 (442 mg, 0.760 mmol), K 2 S 2 0 8 (288 mg, 1 .064 mmol) and K 2 HP0 4 (172 mg, 0.988 mmol) in ACN:water (2: 1 , 12.6 mL) at 90 °C for 1 .5 h. More K 2 S 2 0 8 (62 mg, 0.228 mmol) and K 2 HP0 4 (42 mg, 0.198 mmol) were added and it was heated for an additional 3.5 h then cooled to rt, diluted with ACN and concentrated in vacuo, removing most of the ACN. The mixture was diluted with
- Step 2 fert-Butyl ((1 -(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1 H-tetrazol-5- yl)methyl)carbamate.
- Step 3 using the product of Step 1 (179 mg, 0.415 mmol) and Pd on C (10%, 132 mg) in EtOAc:MeOH (10: 1 , 13.8 mL) for 21 h. The crude residue was used as such in following step.
- Step 3 fert-Butvl 2-(((Z)-(2-(((2 ?,3S)-2-((5-(((fert-butoxycarbonyl)amino)methyl)- 1 H-tetrazol-1 -yl)methyl)-4-oxoazetidin-3-yl)amino)-1 -(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- step 3 using (Z)-2-(((1-(ferf-butoxy)- 2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (214 mg, 0.498 mmol), DIPEA (953 ⁇ _, 5.46 mmol) and HATU (830 mg, 2.18 mmol) in DCM:DMF (5:1 , 3.6 mL) at 0 °C followed by a solution of ferf-butyl ((1-(((2R,3S)-3-amino-4- oxoazetidin-2-yl)methyl)-1 H-tetrazol-5-yl)methyl)carbamate (123 mg, 0.415 mmol) in DCM:DMF (4.3:1 , 3.7 mL).
- Step 4 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)-
- Step 5 2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1 H-tetrazol-1 -yl)methyl)-4-oxo-1 - sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 7 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((5-methyl-2H-tetrazol-2- yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 Compound 1 : Benzyl ((2 ?,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-2H- tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbamate.
- Step 1 Compound 2: Benzyl ((2 ?,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-1H- tetrazol-1 -yl)methyl)-4-oxoazetidin-3-yl)carbamate.
- Step 2 Benzyl ((2 ?,3S)-2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3- yl)carbamate.
- step 2 using benzyl ((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-2/-/-tetrazol-1-yl)methyl)-4-oxoazetidin-3- yl)carbamate (202 mg, 0.433 mmol), K 2 S 2 0 8 (164 mg, 0.606 mmol) and K 2 HP0 4 (98 mg, 0.563 mmol) in ACN:water (2:1 , 7.4 mL) at 90 °C for 1.5 h.
- K 2 S 2 0 8 35 mg, 0.13 mmol
- K 2 HP0 4 20 mg, 0.1 1 mmol
- the mixture was diluted with EtOAc, washed with brine, dried over Na 2 S0 4 and concentrated in vacuo.
- the crude residue was purified via silica gel chromatography (MeOH-DCM, 0-10%), to afford the title compound (1 11 mg, 81 %).
- Step 3 (3S,4f?)-3-amino-4-((5-methvl-2H-tetrazol-2-vl)methyl)azetidin-2-one.
- step 3 using benzyl ((2R,3S)-2-((5-methyl- 2/-/-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbamate (1 1 1 mg, 0.351 mmol) and Pd on C (10%, 50 mg) in EtOAc:MeOH (5: 1 , 7.0 mL) for 3 h.
- EtOAc:MeOH EtOAc:MeOH (5: 1 , 7.0 mL) for 3 h.
- the crude residue was used as such in following step.
- Step 4 fert-Butyl 2-(((Z)-(1 -(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- step 3 using (Z)-2-(((1 -(ferf-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)-2-(2- ((ferf-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (130 mg, 0.302 mmol), DIPEA (158 ⁇ _, 0.906 mmol) and HATU (138 mg, 0.362 mmol) in DCM:DMF (2: 1 , 3.0 mL) at 0 °C followed by a solution of (3S, 4R)-3-amino-4-((5-methyl-2/-/-tetrazol-2-yl)methyl)azetidin-2-one (55 mg, 0.30 mmol) in DCM:DMF (2: 1 , 3.0 mL).
- Step 5 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1 -oxopropan-2-vl)oxv)imino)- 2-(2-((feA -butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-methyl-2H-tetrazol-2- yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- step 4 using ferf-Butyl 2-(((Z)-(1 -(2- ((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-2/-/-tetrazol-2-yl)methyl)-4- oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (179 mg, 0.302 mmol) and SCvDMF (462 mg, 3.02 mmol) in DMF (3.0 mL) for 1 h at rt.
- Step 6 2-(((Z)-(1 -(2-aminothiazol-4-vl)-2-(((2 ?,3S)-2-((5-methyl-2tf-tetrazol-2- yl)methyl)-4-oxo-1 -sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 8 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((5-methyl-1H-tetrazol-1- yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 Benzyl ((2 ?,3S)-2-((5-methyl-1 H-tetrazol-1 -yl)methyl)-4-oxoazetidin-3- yl)carbamate.
- step 2 using benzyl ((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-1 H-tetrazol-1-yl)methyl)-4-oxoazetidin-3- yl)carbamate (221 mg, 0.474 mmol), K 2 S 2 0 8 (179 mg, 0.663 mmol) and K 2 HP0 4 (107 mg, 0.616 mmol) in ACN:water (2:1 , 7.9 mL) at 90 °C for 1.5 h.
- Step 2 (3S,4 ?)-3-amino-4-((5-methyl-1 H-tetrazol-1 -yl)methyl)azetidin-2-one.
- Step 3 fert-Butyl 2-(((Z)-(1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-((5-methyl-1 H-tetrazol-1 -yl)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- step 3 using (Z)-2-(((1-(ferf-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2- ((ferf-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (130 mg, 0.302 mmol), DIPEA (158 ⁇ , 0.906 mmol) and HATU (1 15 mg, 0.302 mmol) in DCM:DMF (2:1 , 3.0 mL) at 0 °C followed by a solution of (3S,4R)-3-amino-4-((5-methyl-1 /-/-tetrazol-1-yl)methyl)azetidin-2-one (55 mg, 0.30 mmol) in DCM:DMF (2:1 , 3.0 mL).
- Step 4 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-methyl-1 H-tetrazol-1 - yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- step 4 using ferf-butyl 2-(((Z)-(1-(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2- ((5-methyl-1 /-/-tetrazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoate (133 mg, 0.224 mmol) and S0 3 « DMF (343 mg, 2.24 mmol) in DMF (2.24 mL) for 1 h at rt.
- Step 5 2-( Z)-(1-(2-aminothiazol-4-vl)-2-(g2 ?.3S)-2- 5-methvl-1 tf-tetrazol-1 - yl)methyl)-4-oxo-1 -sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 9 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin-3- yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid.
- Step 1 benzyl ((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-1 -(2,4- dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate.
- a 20 mL microwave vial was charged with Intermediate A (250 mg, .0522 mmol), 1 ,2,4-triazole (54 mg, 0.784 mmol), K 2 C0 3 (215 mg, 1 .56 mmol), Nal (94 mg, 0.63 mmol) and DMF (2 mL) then heated to 70 °C with stirring.
- step 2 using benzyl ((2R,3S)-2-((1 /-/-1 ,2,4-triazol-1-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3- yl)carbamate (101 mg, 0.224 mmol), K 2 S 2 0 8 (85 mg, 0.313 mmol) and K 2 HP0 4 (50.7 mg, 0.291 mmol) in ACN:water (2:1 , 61.5 mL) while heating for 2 h at 90 °C.
- K 2 S 2 0 8 (18.1 mg, 0.067 mmol) and K 2 HP0 4 (10.1 mg, 0.058 mmol) were added and heated for another 1.5 h. More K 2 S 2 0 8 (18.1 mg, 0.067 mmol) and K 2 HP0 4 (10.1 mg, 0.058 mmol) were added and heated for another hour. It was diluted with ACN and concentrated in vacuo, removing most of the ACN. The mixture was diluted with water/DCM then added EtOAc and the layers separated. The aqueous layer was extracted with EtOAc (5x) and the combined orgnic layers were dried over Na 2 S0 4 .
- Step 3 (3S,4 ?)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one.
- benzyl ((2R,3S)-2-((1 A7-1 ,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbamate 38 mg, 0.126 mmol
- MeOH MeOH
- Pd black 6.7 mg, 0.063 mmol
- formic acid 339 ⁇ , 8.83 mmol
- Step 4 fert-butyl 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxoazetidin-3-yl)amino)-1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 5 (2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-3-((Z)-2-(((1 -(ferf-butoxy)-2- methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4- yl)acetamido)-4-oxoazetidine-1 -sulfonic acid.
- Step 6 2-( Z)-(2-(g2 ?.3S)-2-((1tf-1.2.4-triazol-1-vl)methvl)-4-oxo-1-sulfoazetidin- 3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid.
- Example 10 2-(((Z)-(2-(((2 ?,3S)-2-((3-(aminomethyl)-1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 ((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1 -(2,4-dimethoxybenzyl)-4- oxoazetidin-2-yl)methyl methanesulfonate (3.10 g, 6.48 mmol), ferf-butyl ((1 /-/-1 ,2,4-triazol-3- yl)methyl)carbamate (1.926 g, 9.72 mmol), K 2 C0 3 (1.35 g, 9.72 mmol) and Nal (1.165 g, 7.78 mmol) were slurried in DMF (20 ml_) and heated to 70 °C with stirring.
- Step 2 Prepared in an analogous manner to Example 4, step 2 using the 3- substituted isomer from Step 1 (1.16 g, 2.00 mmol), K 2 S 2 0 8 (756 mg, 2.80 mmol) and K 2 HP0 4 (452 mg, 2.60 mmol) in ACN:water (2:1 , 33.3 mL) while heating for 1.5 h at 90 °C. More K 2 S 2 0 8 (162 mg, 0.599 mmol) and K 2 HP0 4 (90 mg, 0.52 mmol) were added and heated for another 3.5 h, whereupon it was concentrated in vacuo, removing most of the ACN. The mixture was diluted with water/EtOAc and the layers were separated.
- Step 3 fert-butyl ((1 -(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1 H-1 ,2,4- triazol-3-yl)methyl)carbamate.
- Step 4 fert-Butvl 2-(((Z)-(2-(((2 ?,3S)-2-((3-(((fert-butoxycarbonyl)amino)methyl)- 1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxoazetidin-3-yl)amino)-1 -(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 5 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(((ferf- butoxycarbonyl)amino)methyl)-1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 6 2-(((Z)-(2-(((2 ?,3S)-2-((3-(aminomethyl)-1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 11 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((3-(guanidinomethyl)-1H- 1,2,4-triazol-1 -yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoic acid.
- Example 12 2-(((Z)-(2-(((2 ?,3S)-2-((5-(aminomethyl)-1H-1,2,4-triazol-1-yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 Prepared in an analogous manner to Example 4, step 2 using the 5- substituted isomer from Step 1 in Example 10 (361 mg, 0.622 mmol), K 2 S 2 0 8 (235 mg, 0.870 mmol) and K 2 HP0 4 (1 15 mg, 0.808 mmol) in ACN:water (2:1 , 10.4 mL) while heating for 1.5 h at 90 °C. More K 2 S 2 0 8 (50 mg, 0.187 mmol) and K 2 HP0 4 (23 mg, 0.162 mmol) were added and heated for another 3.5 h, whereupon it was concentrated in vacuo, removing most of the ACN. The mixture was diluted with water/EtOAc and the layers were separated.
- Step 2 fert-Butyl ((1-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1 H-1,2,4- triazol-5-yl)methyl)carbamate.
- Step 3 A solution of the product of Step 1 (134 mg, 0.31 1 mmol) in EtOAc:MeOH (5:1 , 10.4 mL) was evaculated and backfilled with argon (2x) followed by addition of Pd on C (10%, 33 mg). The system was evacuated and backfilled with H 2 (3x). After 21 h of stirring MeOH (282 ⁇ _) was added.
- Step 3 fert-Butvl 2-(((Z)-(2-(((2 ?,3S)-2-((5-(((fert-butoxycarbonyl)amino)methyl)- 1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxoazetidin-3-yl)amino)-1 -(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 4 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((ferf- butoxycarbonyl)amino)methyl)-1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 5 2-(((Z)-(2-(((2 ?,3S)-2-((5-(aminomethyl)-1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 13 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((5-(guanidinomethyl)-1H- 1,2,4-triazol-1 -yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoic acid.
- Step 1 Benzyl ((3S,4 ?)-1 -(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxopyridin-1 (2H)- yl)methyl)azetidin-3-yl)carbamate.
- Step 2 Benzyl ((3S,4 ?)-2-oxo-4-((2-oxopyridin-1 (2H)-yl)methyl)azetidin-3- yl)carbamate.
- step 2 using Benzyl ((3S,4R)-1 -(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxopyridin-1 (2/-/)-yl)methyl)azetidin-3- yl)carbamate (361 mg, 0.622 mmol), K 2 S 2 0 8 (225 mg, 0.833 mmol) and K 2 HP0 4 (135 mg, 0.773 mmol) in ACN:water (2: 1 , 9.9 mL) while heating for 1 .5 h at 90 °C.
- Step 3 Compound 1 : 1-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)pyridin- 2(1H)-one.
- Step 3 Compound 2: 1 -(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)piperidin-2- one.
- step 3 A solution of benzyl ((3S,4R)-2-oxo-4-((2- oxopyridin-1 (2/-/)-yl)methyl)azetidin-3-yl)carbamate (157 mg, 0.480 mmol) in EtOH:MeOH (5:1 , 4.8 ml_) was evaculated and backfilled with argon (2x) followed by addition of Pd on C (10%, 33 mg). The system was evacuated and backfilled with H 2 (3x). After 3 h of stirring the mixture was filtered over celite, washing with MeOH and concentrated in vacuo. The crude residue was used as such in following step.
- Step 4 Compound 1 : ferf-Butyl 2-(((Z)-(1-(2-((tert- butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2-oxopyridin-1(2H)- yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 4 Compound 2: ferf-Butyl 2-(((Z)-(1-(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2-oxopiperidin-1- yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoate.
- Step 5 (3S,4 ?)-3-((Z)-2-(((1 -(ferf-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)- 2-(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxopiperidin-1- yl)methyl)azetidine-1 -sulfonic acid, ferf-butyl 2-(((Z)-(1 -(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxopiperidin-1- yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoate (30 mg, 0.049 mmol) in DMF (493 ⁇ _
- StefiJS 2-(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxopiperidin-1 -yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 15 2-(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2-oxopyridin- 1 (2H)-yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoic acid.
- Step 1 (3S,4 ?)-3-((Z)-2-(((1 -(fert-butoxy)-2-methyl-1 -oxopropan-2-yl)oxy)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxopyridin-1 (2H)- yl)methyl)azetidine-1 -sulfonic acid.
- Step 2 2-(((Z)-(1 -(2-aminothiazol-4-vl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2-oxopyridin- 1(2H)-yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoic acid.
- Example 16 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1 -(5-amino-1 ,2,4-thiadiazol-3-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Step 1 (3S,4 ?)-4-((1 H-1 ,2,4-triazol-1 -yl)methyl)-3-aminoazetidin-2-one.
- Step 2 fert-butvl 2-(((Z)-(2-(((2 ?,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4- oxoazetidin-3-yl)amino)-1 -(5-((ferf-butoxycarbonyl)amino)-1 ,2,4-thiadiazol-3-yl)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 3 (2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-3-((Z)-2-(((1 -(ferf-butoxy)-2- methyl-1-oxopropan-2-yl)oxy)imino)-2-(5-((ferf-butoxycarbonyl)amino)-1,2,4-thiadiazol- 3-yl)acetamido)-4-oxoazetidine-1 -sulfonic acid, ferf-butyl 2-(((Z)-(2-(((2R,3S)-2-((1 H- 1 ,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(5-((ferf-butoxycarbonyl)amino)-1 ,2,4- thiadiazol-3-yl)-2-oxoethylidene)amino)oxy)-2-
- Step 4 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1 -(5-amino-1 ,2,4-thiadiazol-3-yl)-2-oxoethylidene)amino)oxy)-2- methylpropanoic acid.
- Example 17 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)acetic acid.
- Step l fert-Butyl 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxoazetidin-3-yl)amino)-1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2- oxoethylidene)amino)oxy)acetate.
- Step 2 (2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-3-((Z)-2-((2-(ferf-butoxy)-2- oxoethoxy)imino)-2-(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4- oxoazetidine-1 -sulfonic acid.
- Step 3 2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)acetic acid.
- Example 18 1 -(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1-(2-aminothiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Step 1 Benzhydryl 1 -(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4- oxoazetidin-3-yl)amino)-1 -(2-((ferf-butoxycarbonyl)amino)thiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylate.
- Step 2 (2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-3-((Z)-2-((1 - ((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1 -sulfonic acid.
- Step 3 1 -(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 -sulfoazetidin- 3-yl)amino)-1 -(2-aminothiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Example 19 1 -(((Z)-(2-(((2 ?,3S)-2-((4-(aminomethyl)-2H-1 ,2,3-triazol-2-yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Step 1 fert-Butvl ((2-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1 ,2,3- triazol-4-yl)methyl)carbamate.
- Step 3 using Intermediate T (1 .20 g, 2.79 mmol) and Pd on C (10%, 830 mg) in EtOAc:MeOH (5: 1 , 24 mL) for 19 h. The crude residue was used as such in following step.
- Step 2 Benzhydryl 1-(((Z)-(2-(((2 ?,3S)-2-((4-(((fert- butoxycarbonyl)amino)methyl)-2H-1 ,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-
- Step 3 (2 ?,3S)-3-((Z)-2-((1-((benzhvdrvloxv)carbonyl)cvclopropoxv)imino)-2-(2- ((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((ferf- butoxycarbonyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 4 1 -(((Z)-(2-(((2 ?,3S)-2-((4-(aminomethyl)-2H-1 ,2,3-triazol-2-yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)- cyclopropanecarboxylic acid.
- Example 20 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((4-(guanidinomethyl)-2H- 1 ,2,3-triazol-2-yl)methyl)-4-oxo-1 -sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-cyclopropanecarboxylic acid.
- Example 21 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)acetic acid.
- Step 1 fert-Butyl 2-(((Z)-(1 -(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2- (((3S,4 ?)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)acetate.
- Step 2 (3S.4 ?)-3-((Z)-2-((2-(fer.-butoxv)-2-oxoethoxv)imino)-2-(2-((ferf- butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxazolidin-3- yl)methyl)azetidine-1 -sulfonic acid.
- Step_3 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1 -sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)acetic acid.
- Example 22 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Step 1 Benzhydryl 1 -(((Z)-(1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo- 2-(((3S,4 ?)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylate.
- Step 2 (3S,4 ?)-3-((Z)-2-((1 -((benzhvdrvloxv)carbonyl)cvclopropoxv)imino)-2-(2- ((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxazolidin-3- yl)methyl)azetidine-1 -sulfonic acid.
- SteE_3 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4 ?)-2-oxo-4-((2- oxooxazolidin-3-yl)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Example 23 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((( ?)-5-methyl-2- oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoic acid
- Step 1 fert-Butyl 2-(((Z)-(1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-(((( ?)-2-hydroxypropyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- a solution of Intermediate L (500 mg, 0.949 mmol) and (R)-propylene oxide (996 ⁇ , 14.2 mmol) in DCM (1.9 ml) was stirred at rt for 16 h whereupon precipitation was observed.
- Step 2 fert-Butyl 2-(((Z)-(1-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)-2- (((2 ?,3S)-2-((( ?)-5-methyl-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoate.
- Step 3 (2 ?,3S)-3-((Z)-2-(((1-(fef -butoxv)-2-methyl-1-oxopropan-2-vl)oxv)imino)- 2-(2-((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((( ?)-5-methyl-2- oxooxazolidin-3-yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 4 2-(((Z)-(1-(2-aminothiazol-4-vl)-2-(((2 ?,3S)-2-((( ?)-5-methyl-2- oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoic acid
- Example 24 2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((( ?)-5-(guanidinomethyl)-2- oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-2-methylpropanoic acid.
- Example 25 1-(((Z)-(2-(((2 ?,3S)-2-((( ?)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)- 4-oxo-1-sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)- cyclopropanecarboxylic acid.
- Step 1 fert-Butyl ((( ?)-3-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2- oxooxazolidin-5-yl)methyl)carbamate.
- Step 3 fert-Butyl ((( ?)-3-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2- oxooxazolidin-5-yl)methyl)carbamate.
- Step 2 Benzhydryl 1-(((Z)-(2-(((2 ?,3S)-2-((( ?)-5-(((fert- butoxycarbonyl)amino)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidin-3- yl)amino)-1 -(2-((fert-butoxycarbonyl)amino)-thiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylate.
- Step 3 (2 ?,3S)-3-((Z)-2-((1-((benzhvdrvloxv)carbonyl)cvclopropoxv)imino)-2-(2- ((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5-(((ferf- butoxycarbonyl)amino)-methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidine-1- sulfonic acid.
- Step 4 1-( Z)-(2-( 2 ?.3S)-2-(q ?)-5-(aminomethvl)-2-oxooxazolidin-3-vl)methvl)- 4-oxo-1-sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)- cyclopropanecarboxylic acid.
- Example 26 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((( ?)-5-(guanidinomethyl)-2- oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-cyclopropanecarboxylic acid.
- Example 27 1 -(((Z)-(2-(((2 ?,3S)-2-((4-(aminomethyl)-1 H-1 ,2,3-triazol-1 -yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylic acid.
- Step 1 fert-Butvl ((1-(((2 ?,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1 H-1,2,3- triazol-4-yl)methyl)carbamate.
- EtOAc/MeOH EtOAc/MeOH
- Step 2 Benzhydryl 1-(((Z)-(2-(((2 ?,3S)-2-((4-(((fert- butoxycarbonyl)amino)methyl)-1H-1,2,3-triazol-1 -yl)methyl)-4-oxoazetidin-3-yl)amino)- 1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2- oxoethylidene)amino)oxy)cyclopropanecarboxylate.
- Step 3 (2 ?.3S)-3-((Z)-2-((1-((benzhvdrvloxv)carbonyl)cvclopropoxv)imino)-2-(2- ((fert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((ferf- butoxycarbonyl)amino)methyl)-1 H-1 ,2,3-triazol-1 -yl)methyl)-4-oxoazetidine-1 -sulfonic acid.
- Step 4 1 -(((Z)-(2-(((2 ?,3S)-2-((4-(aminomethyl)-1 H-1 ,2,3-triazol-1 -yl)methyl)-4- oxo-1 -sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)- cyclopropanecarboxylic acid.
- Example 28 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2 ?,3S)-2-((4-(guanidinomethyl)-1H- 1,2,3-triazol-1 -yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2- oxoethylidene)amino)oxy)-cyclopropanecarboxylic acid.
- the top layer was decanted and the remaining oil was purified by reverse phase prep HPLC (XSelect CSH, 30 x 100 mm, 5 ⁇ , C18 column; ACN-water with 0.1 % formic acid modifier, 60 imL/min), affording the title compound (240 mg, 39%) as a white powder.
- reverse phase prep HPLC XSelect CSH, 30 x 100 mm, 5 ⁇ , C18 column; ACN-water with 0.1 % formic acid modifier, 60 imL/min
- Example 29 (S)-2-(((Z)-(2-(((2 ?,3S)-2-((1 H-1 ,2,4-triazol-1 -yl)methyl)-4-oxo-1 - sulfoazetidin-3-yl)amino)-1 -(2-aminothiazol-4-yl)-2- oxoethylidene)amino)oxy)propanoic acid.
- Step 1 (R)-ferf-Butyl 2-chloropropanoate. Prepared according to Wright et al. Tetrahedron Lett. 1997, 38, 7345. A 500 mL glass bomb was charged with magnesium sulfate (4.21 g, 35.0 mmol) and DCM (43.8 mL). To this suspension was added sulfuric acid (486 ⁇ , 8.75 mmol), drop-wise with vigorus stirring. After 15 min of stirring, (R)-2- chloropropanoic acid (950 mg, 8.75 mmol) was added followed by ferf-butanol (4.20 ml, 43.8 mmol).
- Step 2 (S)-fert-butyl 2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate.
- N- hydroxyphthalimide 517 mg, 3.17 mmol
- potassium carbonate 657 mg, 4.76 mmol
- DMF 4.5 mL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016558569A JP6153674B2 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for treating bacterial infections |
KR1020167024716A KR101733441B1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
PL15714147T PL3122745T3 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
BR112016020333-0A BR112016020333B1 (en) | 2014-03-24 | 2015-03-23 | ORGANIC COMPOUNDS OF MONOBACTAM, THEIR USES, COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS |
LTEP15714147.4T LT3122745T (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
CA2939254A CA2939254C (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
MX2016011822A MX2016011822A (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections. |
EP15714147.4A EP3122745B1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
NZ723114A NZ723114B2 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
DK15714147.4T DK3122745T3 (en) | 2014-03-24 | 2015-03-23 | Organic monobactam compounds for the treatment of bacterial infections |
EA201691766A EA030850B1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
AU2015236369A AU2015236369B2 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
SG11201606711UA SG11201606711UA (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
CN201580015867.7A CN106164072B (en) | 2014-03-24 | 2015-03-23 | For treating the monobactam organic compound of bacterium infection |
MA39777A MA39777B1 (en) | 2014-03-24 | 2015-03-23 | Organic compounds of the monobactam family for the treatment of bacterial infections |
CU2016000131A CU24441B1 (en) | 2014-03-24 | 2015-03-23 | ORGANIC MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
SI201530680T SI3122745T1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
EP18215940.0A EP3511328B1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
UAA201608977A UA121383C2 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
CR20160412A CR20160412A (en) | 2014-03-24 | 2015-03-23 | ORGANIC COMPOUNDS OF MONOBACTAM FOR THE TREATMENT OF BACTERIAL INFECTIONS |
AP2016009374A AP2016009374A0 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
RS20190406A RS58509B1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
ES15714147T ES2719136T3 (en) | 2014-03-24 | 2015-03-23 | Organic monobactam compounds for the treatment of bacterial infections |
PH12016501577A PH12016501577A1 (en) | 2014-03-24 | 2016-08-09 | Monobactam organic compounds for the treatment of bacterial infections |
ZA2016/05565A ZA201605565B (en) | 2014-03-24 | 2016-08-11 | Monobactam organic compounds for the treatment of bacterial infections |
IL247259A IL247259B (en) | 2014-03-24 | 2016-08-14 | Monobactam organic compounds for the treatment of bacterial infections |
HRP20190501TT HRP20190501T1 (en) | 2014-03-24 | 2019-03-13 | Monobactam organic compounds for the treatment of bacterial infections |
CY20191100371T CY1121701T1 (en) | 2014-03-24 | 2019-04-03 | ORGANIC MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461969735P | 2014-03-24 | 2014-03-24 | |
US61/969,735 | 2014-03-24 | ||
US201462088304P | 2014-12-05 | 2014-12-05 | |
US62/088,304 | 2014-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015148379A1 true WO2015148379A1 (en) | 2015-10-01 |
Family
ID=52808201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/022011 WO2015148379A1 (en) | 2014-03-24 | 2015-03-23 | Monobactam organic compounds for the treatment of bacterial infections |
Country Status (36)
Country | Link |
---|---|
US (4) | US9174978B2 (en) |
EP (2) | EP3122745B1 (en) |
JP (1) | JP6153674B2 (en) |
KR (1) | KR101733441B1 (en) |
CN (1) | CN106164072B (en) |
AP (1) | AP2016009374A0 (en) |
AU (1) | AU2015236369B2 (en) |
BR (1) | BR112016020333B1 (en) |
CA (1) | CA2939254C (en) |
CL (1) | CL2016002285A1 (en) |
CU (1) | CU24441B1 (en) |
CY (1) | CY1121701T1 (en) |
DK (2) | DK3122745T3 (en) |
EA (1) | EA030850B1 (en) |
EC (1) | ECSP16073620A (en) |
ES (2) | ES2862203T3 (en) |
GT (1) | GT201600183A (en) |
HR (1) | HRP20190501T1 (en) |
HU (1) | HUE042134T2 (en) |
IL (1) | IL247259B (en) |
LT (1) | LT3122745T (en) |
MA (1) | MA39777B1 (en) |
MX (1) | MX2016011822A (en) |
MY (1) | MY179292A (en) |
PE (1) | PE20161371A1 (en) |
PH (1) | PH12016501577A1 (en) |
PL (1) | PL3122745T3 (en) |
PT (1) | PT3122745T (en) |
RS (1) | RS58509B1 (en) |
SG (1) | SG11201606711UA (en) |
SI (1) | SI3122745T1 (en) |
SV (1) | SV2016005274A (en) |
TW (1) | TWI714525B (en) |
UA (1) | UA121383C2 (en) |
WO (1) | WO2015148379A1 (en) |
ZA (1) | ZA201605565B (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017050218A1 (en) * | 2015-09-23 | 2017-03-30 | Novartis Ag | Salts and solid forms of monobactam antibiotic |
WO2019026004A3 (en) * | 2017-08-02 | 2019-03-14 | Novartis Ag | Process for preparing 1 -(((z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
WO2019058346A1 (en) * | 2017-09-22 | 2019-03-28 | Novartis Ag | Administration of monobactam in combination with antibiotic agent for the treatment of complicated intra-abdominal infection |
WO2019144969A1 (en) | 2018-01-29 | 2019-08-01 | 南京明德新药研发股份有限公司 | Monocyclic β-lactam compound for treating bacterial infection |
WO2020098635A1 (en) | 2018-11-13 | 2020-05-22 | 南京圣和药业股份有限公司 | Monobactam compounds and use therefor |
KR20200058520A (en) * | 2017-10-02 | 2020-05-27 | 머크 샤프 앤드 돔 코포레이션 | Chroman monobactam compounds for treatment of bacterial infections |
WO2020125670A1 (en) | 2018-12-18 | 2020-06-25 | 南京明德新药研发有限公司 | APPLICATION OF MONOCYCLIC β-LACTAM COMPOUND IN PHARMACY |
WO2021098840A1 (en) | 2019-11-22 | 2021-05-27 | 南京明德新药研发有限公司 | SULFONYLUREA RING SUBSTITUTED MONOCYCLIC β-LACTAM ANTIBIOTICS |
WO2021121387A1 (en) | 2019-12-19 | 2021-06-24 | 南京明德新药研发有限公司 | Application of compound in drug preparation |
WO2022185241A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Process for manufacturing a monobactam antibiotic |
WO2022185240A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Formulation of a monobactam antibiotic |
EP4074709A4 (en) * | 2019-12-13 | 2024-01-17 | Evopoint Biosciences Co Ltd | Monocyclic beta-lactam compound and use thereof |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
WO2024077650A1 (en) | 2022-10-12 | 2024-04-18 | 苏州二叶制药有限公司 | Salt form of compound having substituted sulfonylurea ring and crystal form thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180282331A1 (en) | 2015-11-09 | 2018-10-04 | Wockhardt Limited | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS |
KR20180093925A (en) | 2015-12-15 | 2018-08-22 | 머크 샤프 앤드 돔 코포레이션 | Biaryl monobactam compounds for the treatment of bacterial infections and methods for their use |
MX2018010878A (en) | 2016-03-07 | 2018-11-09 | Merck Sharp & Dohme | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections. |
ES2966369T3 (en) | 2017-03-20 | 2024-04-22 | Broad Inst Inc | Compounds and methods for the treatment of parasitic diseases |
KR102455390B1 (en) * | 2017-10-02 | 2022-10-17 | 아릭사 파마슈티컬스 인코포레이티드 | Aztreonam derivatives and uses thereof |
US20200360349A1 (en) * | 2017-11-10 | 2020-11-19 | Novartis Ag | Administration of monobactam for the treatment of urinary tract infection |
KR102017784B1 (en) * | 2018-04-11 | 2019-09-03 | 전북대학교산학협력단 | Medium composition with improved sensitivity and selectivity for detecting Campylobacter and detecting method using thereof |
KR102017785B1 (en) * | 2018-05-17 | 2019-09-03 | 전북대학교산학협력단 | Broth composition with improved sensitivity and selectivity for selectively enriching Campylobacter and detecting method using thereof |
EP3838266A1 (en) | 2019-12-20 | 2021-06-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery |
CN113754651B (en) | 2020-06-02 | 2023-04-18 | 中国医学科学院医药生物技术研究所 | Beta-lactam compound, application and preparation method thereof |
EP4165039A4 (en) * | 2020-07-16 | 2023-06-21 | Ningxia Academy of Agriculture and Forestry Sciences | Novel monobactam compounds, their preparation and use as antibacterial agents |
WO2023091438A1 (en) | 2021-11-18 | 2023-05-25 | Merck Sharp & Dohme Llc | Chromane amidine monobactam antibiotics |
Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0093376A2 (en) * | 1982-04-30 | 1983-11-09 | Takeda Chemical Industries, Ltd. | 1-Sulfo-2-azetidinone derivatives, their production and use |
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
WO1999020758A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
WO1999040196A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
WO2005115451A2 (en) | 2004-04-30 | 2005-12-08 | Isis Innovation Limited | Methods for generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
EP1866339A2 (en) | 2005-03-25 | 2007-12-19 | TolerRx, Inc | Gitr binding molecules and uses therefor |
WO2008039420A2 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
US20100028330A1 (en) | 2002-12-23 | 2010-02-04 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-pd1 antibodies |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2010027827A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
WO2011051726A2 (en) | 2009-10-30 | 2011-05-05 | Isis Innovation Ltd | Treatment of obesity |
WO2011061760A1 (en) | 2009-11-18 | 2011-05-26 | Cadila Healthcare Limited | Novel antithrombotic agents |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011090754A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Polypeptide heterodimers and uses thereof |
US20120039906A1 (en) | 2009-02-09 | 2012-02-16 | INSER (Institut National de la Recherche Medicale) | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof |
US20120114649A1 (en) | 2008-08-25 | 2012-05-10 | Amplimmune, Inc. Delaware | Compositions of pd-1 antagonists and methods of use |
WO2012073138A1 (en) | 2010-11-29 | 2012-06-07 | Pfizer Inc. | Monobactams |
US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
WO2013028590A1 (en) | 2011-08-25 | 2013-02-28 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
WO2013038330A1 (en) | 2011-09-13 | 2013-03-21 | Wockhardt Limited | Nitrogen containing compounds and their use |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
WO2013110643A1 (en) | 2012-01-24 | 2013-08-01 | Aicuris Gmbh & Co. Kg | Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents |
WO2013122888A2 (en) | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
WO2013124826A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors |
US20130225554A1 (en) | 2011-12-02 | 2013-08-29 | Naeja Pharmaceutical Inc. | New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2013149136A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | ISOXAZOLE β-LACTAMASE INHIBITORS |
US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2014033560A1 (en) | 2012-08-25 | 2014-03-06 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ196202A (en) | 1980-02-07 | 1984-07-31 | Squibb & Sons Inc | Beta-lactam antibiotics (of azetidine-sulphonic acid type) |
EP0048953B1 (en) | 1980-09-29 | 1988-03-09 | E.R. Squibb & Sons, Inc. | Beta-lactam antibiotics |
US4775670A (en) | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
WO1982001873A1 (en) * | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
US4782147A (en) | 1980-12-05 | 1988-11-01 | Takeda Chemical Industries, Ltd. | 1-sulfo-2-oxoazetidine derivatives and their production |
JPS58189176A (en) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | 1-sulfo-2-azetidinone derivative and its preparation |
JPS58210061A (en) * | 1982-05-31 | 1983-12-07 | Takeda Chem Ind Ltd | 1-sulfo-2-oxoazetidine derivative, its preparation and use |
CA1262128A (en) | 1981-08-27 | 1989-10-03 | Christian N. Hubschwerlen | .beta.-lactams |
IL67451A (en) | 1981-12-25 | 1987-10-20 | Takeda Chemical Industries Ltd | 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them |
KR900005112B1 (en) | 1982-05-31 | 1990-07-19 | 반유세이야꾸 가부시끼가이샤 | Process for preparing 2-oxo-1-azetidine sulfonic acid derivatives |
EP0096297B1 (en) | 1982-06-03 | 1988-06-15 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives |
JPS6153282A (en) | 1984-08-22 | 1986-03-17 | Banyu Pharmaceut Co Ltd | Monocyclic beta-lactam derivative |
JPS6153283A (en) | 1984-08-24 | 1986-03-17 | Banyu Pharmaceut Co Ltd | 2-oxo-1-azetidinesulfonic acid derivative |
US4610824A (en) | 1984-10-09 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Hydrazide derivatives of monocyclic beta-lactam antibiotics |
US5112968A (en) | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
PT2960244T (en) | 2008-10-31 | 2016-11-02 | Shionogi & Co | Cephalosporin having catechol group |
JP2012027846A (en) | 2010-07-27 | 2012-02-09 | Sony Corp | Information processing unit, information display method and computer program |
CN103044416A (en) | 2012-12-17 | 2013-04-17 | 浙江华方药业有限责任公司 | Synthetic method of Carumonam sodium |
US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
-
2015
- 2015-03-23 SG SG11201606711UA patent/SG11201606711UA/en unknown
- 2015-03-23 AP AP2016009374A patent/AP2016009374A0/en unknown
- 2015-03-23 US US14/665,245 patent/US9174978B2/en active Active
- 2015-03-23 PL PL15714147T patent/PL3122745T3/en unknown
- 2015-03-23 RS RS20190406A patent/RS58509B1/en unknown
- 2015-03-23 AU AU2015236369A patent/AU2015236369B2/en active Active
- 2015-03-23 TW TW104109243A patent/TWI714525B/en active
- 2015-03-23 DK DK15714147.4T patent/DK3122745T3/en active
- 2015-03-23 DK DK18215940.0T patent/DK3511328T3/en active
- 2015-03-23 HU HUE15714147A patent/HUE042134T2/en unknown
- 2015-03-23 KR KR1020167024716A patent/KR101733441B1/en active IP Right Grant
- 2015-03-23 MA MA39777A patent/MA39777B1/en unknown
- 2015-03-23 MX MX2016011822A patent/MX2016011822A/en active IP Right Grant
- 2015-03-23 CA CA2939254A patent/CA2939254C/en active Active
- 2015-03-23 UA UAA201608977A patent/UA121383C2/en unknown
- 2015-03-23 SI SI201530680T patent/SI3122745T1/en unknown
- 2015-03-23 MY MYPI2016702871A patent/MY179292A/en unknown
- 2015-03-23 CU CU2016000131A patent/CU24441B1/en unknown
- 2015-03-23 BR BR112016020333-0A patent/BR112016020333B1/en active IP Right Grant
- 2015-03-23 EP EP15714147.4A patent/EP3122745B1/en active Active
- 2015-03-23 LT LTEP15714147.4T patent/LT3122745T/en unknown
- 2015-03-23 ES ES18215940T patent/ES2862203T3/en active Active
- 2015-03-23 ES ES15714147T patent/ES2719136T3/en active Active
- 2015-03-23 EP EP18215940.0A patent/EP3511328B1/en active Active
- 2015-03-23 PT PT15714147T patent/PT3122745T/en unknown
- 2015-03-23 PE PE2016001601A patent/PE20161371A1/en unknown
- 2015-03-23 JP JP2016558569A patent/JP6153674B2/en active Active
- 2015-03-23 WO PCT/US2015/022011 patent/WO2015148379A1/en active Application Filing
- 2015-03-23 EA EA201691766A patent/EA030850B1/en not_active IP Right Cessation
- 2015-03-23 CN CN201580015867.7A patent/CN106164072B/en active Active
- 2015-09-22 US US14/861,797 patent/US10369138B2/en active Active
-
2016
- 2016-08-09 PH PH12016501577A patent/PH12016501577A1/en unknown
- 2016-08-11 ZA ZA2016/05565A patent/ZA201605565B/en unknown
- 2016-08-14 IL IL247259A patent/IL247259B/en active IP Right Grant
- 2016-09-09 CL CL2016002285A patent/CL2016002285A1/en unknown
- 2016-09-12 SV SV2016005274A patent/SV2016005274A/en unknown
- 2016-09-12 EC ECIEPI201673620A patent/ECSP16073620A/en unknown
- 2016-09-12 GT GT201600183A patent/GT201600183A/en unknown
-
2019
- 2019-03-13 HR HRP20190501TT patent/HRP20190501T1/en unknown
- 2019-04-03 CY CY20191100371T patent/CY1121701T1/en unknown
- 2019-04-10 US US16/380,243 patent/US20190231752A1/en not_active Abandoned
-
2020
- 2020-03-19 US US16/823,485 patent/US20200276169A1/en not_active Abandoned
Patent Citations (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
EP0093376A2 (en) * | 1982-04-30 | 1983-11-09 | Takeda Chemical Industries, Ltd. | 1-Sulfo-2-azetidinone derivatives, their production and use |
US7025962B1 (en) | 1996-08-16 | 2006-04-11 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
WO1999020758A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
WO1999040196A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
US20100028330A1 (en) | 2002-12-23 | 2010-02-04 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-pd1 antibodies |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
WO2005115451A2 (en) | 2004-04-30 | 2005-12-08 | Isis Innovation Limited | Methods for generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
EP1866339A2 (en) | 2005-03-25 | 2007-12-19 | TolerRx, Inc | Gitr binding molecules and uses therefor |
US8388967B2 (en) | 2005-03-25 | 2013-03-05 | Gitr, Inc. | Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies |
US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EP2161336A1 (en) | 2005-05-09 | 2010-03-10 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US7943743B2 (en) | 2005-07-01 | 2011-05-17 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
WO2008039420A2 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
US20110150892A1 (en) | 2008-08-11 | 2011-06-23 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof |
WO2010019570A2 (en) | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
US8609089B2 (en) | 2008-08-25 | 2013-12-17 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
WO2010027827A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
US20120114649A1 (en) | 2008-08-25 | 2012-05-10 | Amplimmune, Inc. Delaware | Compositions of pd-1 antagonists and methods of use |
US8586023B2 (en) | 2008-09-12 | 2013-11-19 | Mie University | Cell capable of expressing exogenous GITR ligand |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US20120039906A1 (en) | 2009-02-09 | 2012-02-16 | INSER (Institut National de la Recherche Medicale) | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
WO2011051726A2 (en) | 2009-10-30 | 2011-05-05 | Isis Innovation Ltd | Treatment of obesity |
WO2011061760A1 (en) | 2009-11-18 | 2011-05-26 | Cadila Healthcare Limited | Novel antithrombotic agents |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011090754A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Polypeptide heterodimers and uses thereof |
WO2012073138A1 (en) | 2010-11-29 | 2012-06-07 | Pfizer Inc. | Monobactams |
WO2013028590A1 (en) | 2011-08-25 | 2013-02-28 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
WO2013038330A1 (en) | 2011-09-13 | 2013-03-21 | Wockhardt Limited | Nitrogen containing compounds and their use |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
US20130225554A1 (en) | 2011-12-02 | 2013-08-29 | Naeja Pharmaceutical Inc. | New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
WO2013110643A1 (en) | 2012-01-24 | 2013-08-01 | Aicuris Gmbh & Co. Kg | Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents |
WO2013122888A2 (en) | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
WO2013124826A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors |
WO2013149136A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | ISOXAZOLE β-LACTAMASE INHIBITORS |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2014008218A1 (en) | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
WO2014033560A1 (en) | 2012-08-25 | 2014-03-06 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
Non-Patent Citations (31)
Title |
---|
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
"The Peptides", vol. 3, 1981, ACADEMIC PRESS |
BENNETT ET AL., J. IMMUNOL., vol. 170, 2003, pages 711 - 8 |
BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314 |
BLANK, C. ET AL., IMMUNOL. IMMUNOTHER., vol. 56, no. 5, 29 December 2006 (2006-12-29), pages 739 - 745 |
BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66 |
DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7 |
H.-D. JAKUBKE; H. JESCHKEIT: "Aminosauren, Peptide, Proteine", 1982, VERLAG CHEMIE |
HAMID, O. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 2, 2013, pages 134 - 44 |
HOUBEN WEYL: "Methoden der organischen Chemie", vol. 15/1, 1974, GEORG THIEME VERLAG |
HUBSCHWERLEN, C.; SCHMID, G., HELV. CHIM. ACTA, vol. 66, 1983, pages 2206 - 2209 |
ISHIDA, Y. ET AL., EMBO J., vol. 11, 1992, pages 3887 - 3895 |
IWAI ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 99, 2002, pages 12293 - 7 |
J BACTERIOL, vol. 183, no. 21, pages 6384 - 6393 |
J BACTERIOL., vol. 7, no. 14, 17 July 1995 (1995-07-17), pages 4121 - 30 |
J. F. W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
JOCHEN LEHMANN: "Chemie der Kohlenhydrate: Monosaccharide und Derivate", 1974, GEORG THIEME VERLAG |
KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100 |
MALMSTROM ET AL., BIOORG. MED. CHEM. LETT., vol. 22, 2012, pages 5293 |
MASTALERZ ET AL., J. MED. CHEM., vol. 31, 1988, pages 1190 |
OKAZAKI ET AL., CURR OPIN IMMUNOL, vol. 14, 2002, pages 391779 - 82 |
PLATER ET AL., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 1633 |
RUBINSZTAJN ET AL., TETRAHEDRON LETT., vol. 33, no. 14, 1992, pages 1821 - 1824 |
SEKI ET AL., SYNLETT, 1995, pages 609 - 611 |
SHARPLESS, K. B., SYNTHESIS, vol. 9, 2005, pages 1514 |
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY |
WOO ET AL., CANCER RES., vol. 72, no. 4, 2012, pages 917 - 27 |
WRIGHT ET AL., TETRAHEDRON LETT., vol. 38, 1997, pages 7345 |
YAMAWAKI ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2007, pages 6716 - 6732 |
YAMAWAKI ET AL., BIOORG. MED. CHEM., vol. 15, 2007, pages 6716 |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10919887B2 (en) | 2015-09-23 | 2021-02-16 | Novartis Ag | Salts and solid forms of a monobactam antibiotic |
CN108137573A (en) * | 2015-09-23 | 2018-06-08 | 诺华股份有限公司 | The salt and solid form of monobactam antibiotic |
JP2018528241A (en) * | 2015-09-23 | 2018-09-27 | ノバルティス アーゲー | Salt and solid forms of monobactam antibiotics |
WO2017050218A1 (en) * | 2015-09-23 | 2017-03-30 | Novartis Ag | Salts and solid forms of monobactam antibiotic |
CN108137573B (en) * | 2015-09-23 | 2021-06-11 | 诺华股份有限公司 | Salts and solid forms of monocyclolactam antibiotics |
AU2016327264B2 (en) * | 2015-09-23 | 2019-06-27 | Novartis Ag | Salts and solid forms of monobactam antibiotic |
EA037569B1 (en) * | 2015-09-23 | 2021-04-15 | Новартис Аг | Salts of monobactam antibiotic and use thereof |
US11414411B2 (en) | 2017-08-02 | 2022-08-16 | Novartis Ag | Chemical process for manufacturing monobactam antibiotic and intermediates thereof |
AU2018311521B2 (en) * | 2017-08-02 | 2022-03-03 | Novartis Ag | Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
CN111094281B (en) * | 2017-08-02 | 2023-08-29 | 诺华股份有限公司 | Chemical process for preparing monolactam antibiotics and intermediates thereof |
CN111094281A (en) * | 2017-08-02 | 2020-05-01 | 诺华股份有限公司 | Chemical process for the preparation of monobactam antibiotics and intermediates thereof |
WO2019026004A3 (en) * | 2017-08-02 | 2019-03-14 | Novartis Ag | Process for preparing 1 -(((z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
WO2019058346A1 (en) * | 2017-09-22 | 2019-03-28 | Novartis Ag | Administration of monobactam in combination with antibiotic agent for the treatment of complicated intra-abdominal infection |
KR20200058520A (en) * | 2017-10-02 | 2020-05-27 | 머크 샤프 앤드 돔 코포레이션 | Chroman monobactam compounds for treatment of bacterial infections |
US11433055B2 (en) | 2017-10-02 | 2022-09-06 | Merck Sharp & Dohme Llc | Chromane monobactam compounds for the treatment of bacterial infections |
KR102425959B1 (en) | 2017-10-02 | 2022-07-27 | 머크 샤프 앤드 돔 코포레이션 | Chroman Monobactam Compound for Treatment of Bacterial Infections |
WO2019144969A1 (en) | 2018-01-29 | 2019-08-01 | 南京明德新药研发股份有限公司 | Monocyclic β-lactam compound for treating bacterial infection |
US11459323B2 (en) | 2018-01-29 | 2022-10-04 | Medshine Discovery Inc. | Monocyclic β-lactam compound for treating bacterial infection |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
WO2020098635A1 (en) | 2018-11-13 | 2020-05-22 | 南京圣和药业股份有限公司 | Monobactam compounds and use therefor |
WO2020125670A1 (en) | 2018-12-18 | 2020-06-25 | 南京明德新药研发有限公司 | APPLICATION OF MONOCYCLIC β-LACTAM COMPOUND IN PHARMACY |
WO2021098840A1 (en) | 2019-11-22 | 2021-05-27 | 南京明德新药研发有限公司 | SULFONYLUREA RING SUBSTITUTED MONOCYCLIC β-LACTAM ANTIBIOTICS |
EP4074709A4 (en) * | 2019-12-13 | 2024-01-17 | Evopoint Biosciences Co Ltd | Monocyclic beta-lactam compound and use thereof |
WO2021121387A1 (en) | 2019-12-19 | 2021-06-24 | 南京明德新药研发有限公司 | Application of compound in drug preparation |
WO2022185241A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Process for manufacturing a monobactam antibiotic |
WO2022185240A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Formulation of a monobactam antibiotic |
WO2024077650A1 (en) | 2022-10-12 | 2024-04-18 | 苏州二叶制药有限公司 | Salt form of compound having substituted sulfonylurea ring and crystal form thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3122745B1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
US10544130B2 (en) | Metallo-beta-lactamase inhibitors | |
US20200055825A1 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
US20220298134A1 (en) | Heterocyclic compounds for use in the treatment of cancer | |
MX2009001436A (en) | Hepatitis c virus inhibitors. | |
AU2007286222A1 (en) | Hepatitis C virus inhibitors | |
US11332459B2 (en) | Benzimidazole derivatives and their uses | |
JP2021511363A (en) | Aminopyrrolotriazine as a kinase inhibitor | |
US11447479B2 (en) | Compounds active towards nuclear receptors | |
US10597396B2 (en) | Beta-lactamase inhibitors | |
US20220227733A1 (en) | Pd-l1 antagonist compound | |
NZ723114B2 (en) | Monobactam organic compounds for the treatment of bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15714147 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016501577 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2939254 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247259 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2015236369 Country of ref document: AU Date of ref document: 20150323 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167024716 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001601-2016 Country of ref document: PE Ref document number: MX/A/2016/011822 Country of ref document: MX Ref document number: CR2016-000412 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2016/0001842 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2016558569 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201691766 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201608977 Country of ref document: UA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015714147 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015714147 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016020333 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112016020333 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160902 |